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Foreword
 
The development of the Comprehensive STD Prevention Systems (CSPS) program 
announcement marked a major milestone in the efforts of CDC to implement the 
recommendations of the Institute of Medicine report, The Hidden Epidemic, Con­
fronting Sexually Transmitted Diseases, 1997.  With the publication of these STD 
Program Operations Guidelines, CDC is providing STD programs with the guid­
ance to further develop the essential functions of the CSPS. Each chapter of the 
guidelines corresponds to an essential function of the CSPS announcement. This 
chapter on medical and laboratory services is one of nine. 
With many STDs, such as syphilis, on a downward trend, now is the time to 
employ new strategies and new ways of looking at STD control. Included in these 
guidelines are chapters that cover areas new to many STD programs, such as com­
munity and individual behavior change, and new initiatives, such as syphilis elimi­
nation. Each STD program should use these Program Operations Guidelines when 
deciding where to place priorities and resources. It is our hope that these guidelines 
will be widely distributed and used by STD programs across the country in the 
future planning and management of their prevention efforts. 
Judith N. Wasserheit 
Director 
Division of STD Prevention 
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Introduction
 
These guidelines for STD prevention program operations are based on the essential functions contained in the Comprehensive STD Preven­
tion Systems (CSPS) program announcement. The 
guidelines are divided into chapters that follow the 
eight major CSPS sections: Leadership and Program 
Management, Evaluation, Training and Professional 
Development, Surveillance and Data Management, 
Partner Services, Medical and Laboratory Services, 
Community and Individual Behavior Change, Out­
break Response, and Areas of Special Emphasis. Ar­
eas of special emphasis include corrections, adoles­
cents, managed care, STD/HIV interaction, syphilis 
elimination, and other high-risk populations. 
The target audience for these guidelines is public 
health personnel and other persons involved in man­
aging STD prevention programs. The purpose of these 
guidelines is to further STD prevention by providing a 
resource to assist in the design, implementation, and 
evaluation of STD prevention and control programs. 
The guidelines were developed by a workgroup of 
18 members from program operations, research, sur­
veillance and data management, training, and evalua­
tion. Members included CDC headquarters and field 
staff, as well as non-CDC employees in State STD Pro­
grams and university settings. 
For each chapter, subgroups were formed and as­
signed the task of developing a chapter, using evidence-
based information, when available. Each subgroup was 
comprised of members of the workgroup plus subject 
matter experts in a particular field. All subgroups used 
causal pathways to help determine key questions for 
literature searches. Literature searches were conducted 
on key questions for each chapter. Many of the searches 
found little evidence-based information on particular 
topics. The chapter containing the most evidence-based 
guidance is on partner services. In future versions of 
this guidance, evidence-based information will be ex­
panded. Recommendations are included in each chap­
ter. Because programs are unique, diverse, and locally 
driven, recommendations are guidelines for operation 
rather than standards or options. 
In developing these guidelines the workgroup fol­
lowed the CDC publication “CDC Guidelines -- Im­
proving the Quality”, published in September, 1996. 
The intent in writing the guidelines was to address 
appropriate issues such as the relevance of the health 
problem, the magnitude of the problem, the nature of 
the intervention, the guideline development methods, 
the strength of the evidence, the cost effectiveness, 
implementation issues, evaluation issues, and recom­
mendations. 
STD prevention programs exist in highly diverse, 
complex, and dynamic social and health service set­
tings. There are significant differences in availability 
of resources and range and extent of services among 
different project areas. These differences include the 
level of various STDs and health conditions in com­
munities, the level of preventive health services avail­
able, and the amount of financial resources available 
to provide STD services. Therefore, these guidelines 
should be adapted to local area needs. We have given 
broad, general recommendations that can be used by 
all program areas. However, each must be used in con­
junction with local area needs and expectations. All 
STD programs should establish priorities, examine 
options, calculate resources, evaluate the demographic 
distribution of the diseases to be prevented and con­
trolled, and adopt appropriate strategies. The success 
of the program will depend directly upon how well 
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program personnel carry out specific day to day re­
sponsibilities in implementing these strategies to in­
terrupt disease transmission and minimize long term 
adverse health effects of STDs. 
In this document we use a variety of terms familiar 
to STD readers. For purposes of simplification, we will 
use the word patient when referring to either patients 
or clients. Because some STD programs are combined 
with HIV programs and others are separate, we will 
use the term STD prevention program when referring 
to either STD programs or combined STD/HIV programs. 
These guidelines, based on the CSPS program an­
nouncement, cover many topics new to program op­
erations. Please note, however, that these guidelines 
replace all or parts of the following documents: 
• Guidelines for STD Control Program Operations, 
1985. 
• Quality Assurance Guidelines for Managing the 
Performance of DIS in STD Control, 1985. 
• Guidelines for STD Education, 1985. 
• STD Clinical Practice Guidelines, Part 1, 1991. 
The following websites may be useful: 
• CDC	 www.cdc.gov 
• NCHSTP	 www.cdc.gov/nchstp/od/nchstp.html 
• DSTD	 www.cdc.gov/nchstp/dstd/dstdp.html 
• OSHA	 www.osha.gov 
• Surveillance in a Suitcase	 www.cdc.gov/epo/surveillancein/ 
• Test Complexity Database	 www.phppo.cdc.gov/dls/clia/testcat.asp 
• Sample Purchasing Specifications	 www.gwu.edu/~chsrp/ 
• STD Memoranda of Understanding	 www.gwumc.edu/chpr/mcph/moustd.pdf 
• National Plan to Eliminate Syphilis	 www.cdc.gov/Stopsyphilis/ 
• Network Mapping	 www.heinz.cmu.edu/project/INSNA/soft_inf.html 
• Domestic Violence	 www.ojp.usdoj.gov/vawo/ 
• Prevention Training Centers	 www.stdhivpreventiontraining.org 
•	 Regional Title X Training Centers www.famplan.org 
www.cicatelli.org 
www.jba-cht.com 
• HEDIS	 www.cdc.gov/nchstp/dstd/hedis.htm 
• Put Prevention Into Practice	 www.ahrq.gov/clinic/ppipix.htm 
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Medical and Laboratory Services
 
INTRODUCTION 
High quality, accessible medical and laboratory ser­
vices are essential elements in the prevention of sexu­
ally transmitted diseases within any community. While 
private providers, managed care agencies, and institu­
tions such as emergency rooms and correctional fa­
cilities have become increasingly central to STD screen­
ing, diagnosis, and treatment services, categorical STD 
clinics remain an important source of accessible, af­
fordable, and expert clinical care in most communi­
ties. With the integration of HIV testing, counseling, 
and treatment into routine STD care, the demand for 
services in STD clinics has increased. Therefore, it is 
important to examine all elements of clinic operation, 
from administration to the range and quality of ser­
vices offered since they affect the ability of an STD 
clinic to play a crucial role in disease intervention. 
Though this chapter specifically addresses guidance 
for STD clinics in providing medical services, much of 
the information is relevant to any STD service pro­
vider or agency. 
ACCESSIBILITY 
The most common reasons given by clients for choos­
ing an STD clinic for care are the availability of walk-
in services or same-day appointments, lower cost of 
care, privacy or confidentiality concerns, convenience 
of the clinic’s location, and expert care (Celum, 1997). 
Medical services at the public STD clinic should be 
low or no cost, confidential, and convenient to avoid 
the creation of barriers between the patient and the 
accessibility of services. It is important that the clinic 
be easily accessible by public transportation and the 
hours of operation should be varied and flexible to 
avoid long waiting times and turning patients away 
(Landry, 1996; Beilenson, 1995). This can be accom­
plished by evaluating waiting times and the number of 
patients turned away. To make services accessible, clin­
ics should develop systems that provide walk-in ser­
vices and same day appointments, remain open dur­
ing lunchtime hours, provide services outside standard 
business hours (evening and Saturday services), and 
accommodate patients with immediate scheduling 
needs e.g., return visits and symptomatic patients, by 
operating at least three days a week. If a clinic is un­
able to provide services three days a week, a referral 
system should be in place so that persons needing im­
mediate services can be accommodated. Expansion of 
clinical services, including the addition of evening 
hours, leads to an increase in overall clinic attendance 
and increased numbers of STD cases diagnosed (Lyttle, 
1994; Hart, 1992). Despite convenient hours, outreach 
activities may be needed to access specific at-risk popu­
lations and should be strongly considered. For example, 
collaboration with a drug services program may be 
more likely to result in delivery of STD services to cli­
ents (Coutinho, 1987; Van den Hoek, 1997). The gen­
eral public should be able to easily determine how to 
obtain specialized STD services. This can be done 
through listing the clinic in the telephone directory and 
among frequently called numbers or under a heading 
that is readily understandable to patients through ad­
vertising in locations and through media utilized by 
high-risk populations, listing in community medical 
resource directories, and providing automated tele­
phone services to provide information about clinic 
hours to after hours callers. 
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 Recommendations 
•	 The clinic facility must be physically acces­
sible in accordance with the Americans with 
Disabilities Act. 
•	 Clinics should be located so that they are 
readily accessible through public and private 
transportation from residential areas. 
•	 The general public should be able to easily de­
termine how to obtain specialized STD services. 
•	 Clinic hours and staffing should be sufficient 
to accommodate patients, with minimal pa­
tients turned away. 
•	 A system to periodically assess clinic user (or 
patient) satisfaction with services should be in 
place. 
•	 No patient should be denied care for lack of 
money. Medical services should be at no 
charge, minimal, or based on a sliding scale. 
• Fees should not be assessed for examining per­
sons referred by a disease intervention special­
ist. 
RANGE OF SERVICES 
STD clinics should provide basic STD prevention ser­
vices emphasizing the particular needs of the at- risk 
populations within the community. At a minimum, 
clinics should be able to diagnose and treat syphilis 
(all stages), gonorrhea, chlamydia, bacterial vaginosis, 
trichomoniasis, and candida. Ideally, clinics should also 
be able to diagnose and treat genital warts and genital 
herpes, vaccinate for viral hepatitis, and perform Pap 
smears and pregnancy tests. Other services such as 
integrating HIV-related services and family planning 
services into routine STD services may lengthen the 
clinic visit, but may also address important patient 
needs. Condoms and primary prevention counseling 
should be provided at all STD clinics to help in the 
prevention and control of disease. A procedure should 
be established to accord priority care to any patient 
referred by a DIS, receiving HIV prevention counsel­
ing, or returning for follow-up examinations with an 
appointment. STD programs should also be prepared 
to handle the increased volume of patients that may 
occur with any outbreaks (see the Outbreak Response 
Plan chapter for details). 
Recommendations 
•	 At a minimum, clinics should have the capa­
bility to accurately diagnose and treat bacte­
rial STDs. 
•	 Clinics should have the capacity to distribute 
medications for diseases diagnosed in the 
clinic. At a minimum, medications must be 
available for locally prevalent STDs, with pre­
scriptions available for diagnosed diseases not 
prevalent in the community. 
•	 Clinics should provide condoms and counsel­
ing on primary prevention to all patients. 
•	 Clinics providing Pap smears should have spe­
cific protocols for follow-up of abnormal results 
that include guidelines for colposcopy referral. 
•	 Clinics providing pregnancy tests should have 
specific protocols for follow-up and referral 
of positive tests. 
•	 Clinics should collaborate with immunization 
programs and viral hepatitis programs to pro­
vide hepatitis B vaccinations to those at risk. 
•	 Clinics should provide the basic range of HIV 
related services specified in state and federal 
statutes and, for patient convenience, should 
offer as many as possible on site (e.g., coun­
seling and testing, partner services). 
•	 Confidential counseling and testing for HIV 
should be offered at the time of the STD visit 
so that patients do not have to visit separate 
clinics or make return visits. 
•	 Confidential counseling and testing for STDs, 
including HIV, should not be denied because 
a patient refuses other STD services. 
•	 Anonymous HIV testing should be available 
on site for patients requesting the service or 
at community sites convenient to patients. 
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Recommendations, continued 
•	 Written policy and procedures should be in place 
for the referral of patients for HIV early inter­
vention services (e.g., continuing medical evalu­
ation, tuberculosis and immune system testing, 
treatment, and support group counseling). 
•	 When not offered on site, the mechanisms for 
referral should be established for relevant 
health services (e.g., family planning, prena­
tal, adult immunizations, drug counseling). 
CLINIC ENVIRONMENT 
The quality of the physical facility as well as the pro­
fessional attitudes of staff influence a patient’s impres­
sion of services. Distinct public health benefits can 
come from maintaining an aesthetically pleasing and 
professional environment. The environment should 
reinforce confidentiality and support health education 
directed toward positive behavior change. 
Recommendations 
Facility 
•	 The building in which a STD clinic is located 
should have signs making it easy to locate. 
Signs at the building entrance should be easy 
to read and should clearly list STD among the 
services. 
•	 Waiting areas should contain accessible pa­
tient education (i.e., handouts, posters, pam­
phlets, or audiovisuals) that emphasize risk 
reduction behaviors for the prevention of 
STDs, HIV, and viral hepatitis. 
•	 Examination rooms should be clean and pri­
vate and should have adequate equipment and 
supplies for physical examinations and specimen 
collection for both male and female patients. 
•	 The number of examination rooms should be 
adequate to accommodate the number of cli­
nicians (at least one room per clinician) and 
to serve patients promptly during the normal 
working day. 
Recommendations, continued 
Patient Considerations 
•	 Patient confidentiality must be maintained. 
Confidentiality should be promoted by using 
a system other than names when calling pa­
tients from waiting areas. 
•	 Clinic personnel should be courteous and re­
spectful of patients. 
•	 Patients should be told what to expect during 
the clinic visit, including being told STDs for 
which they are being tested and the common 
ones for which they are not being tested. 
•	 All clinic staff should develop and maintain 
cross-cultural awareness and display cultural 
sensitivity. 
•	 An adequate portion of the clinic staff should 
have bilingual fluency that facilitates services 
to those patients who do not speak English. 
•	 Clinics should assess the need for physical se­
curity during clinic sessions and have security 
protocols in place. 
REGISTRATION PROCESS 
Registration is a critical component of an efficient and 
successful clinic. A well-trained clerical staff and a well-
organized clerical system expedite patient flow at this 
critical point. Registration personnel see patients first; 
therefore, they set the tone for the visit and must be 
aware of their role in influencing patient attitudes. 
Clinical, counseling, or other services must never 
be denied because a patient is unable or declines to 
provide identification. Patient address and locating 
information should be updated at every visit in the 
event that follow-up is needed. When a substantial 
proportion of patients needing follow-up testing, treat­
ment, or disease intervention services cannot be lo­
cated because of false identities or addresses, the clinic 
should strongly consider other methods to insure fol­
low-up, including a policy of requesting identification 
at registration. It may be useful to have a supervisor 
speak with patients who cannot provide identification 
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 to explain the importance of obtaining accurate infor­
mation for the purpose of follow-up. Clinics that of­
fer anonymous HIV antibody counseling and testing 
should advertise a waiver of positive identification for 
persons seeking that service only. 
Clinics should have some system of “fast-track” 
registration, such as assigning letters instead of num­
bers, for persons who have priority referrals or who 
re-visit. The DIS referred or “expected-in” file should 
be checked each time a person registers for STD ser­
vices to ensure that persons who have been referred 
by a DIS for examination, or those who need repeat 
serologic testing or HIV counseling are identified and 
receive these services. The “expected- in” file contains 
a brief summary of treatment or other information on 
persons needing follow-up for disease intervention ser­
vices. The file may include the following: persons with 
positive STD/HIV test results in need of treatment, 
persons referred either by the STD clinic or other fa­
cilities, sex partners or cluster suspects/associates of 
diagnosed patients, and persons who need special re­
peat testing. With the registration staff attaching the 
expected-in form to a medical chart, a clinician will 
have additional epidemiologic information and medi­
cal information needed to provide immediate and ap­
propriate treatment. 
Recommendations 
Confidentiality 
Registration information should be obtained 
in a confidential manner. 
Acoustical barriers separating clerks from 
waiting areas in addition to methods of self 
registration should be considered when dis­
tance does not prevent persons from overhear­
ing those who are registering. 
Information collected at the registration desk 
should be relevant: locating and demographic 
data, type of visit (referral, appointment, or 
walk-in); clerks should avoid discussing the 
medical reason for the visit including any 
symptoms or medical history. 
Recommendations, continued 
•	 Patient address should be verified at every visit 
in the event that follow up is needed. 
Procedure 
• Telephone reports of test results must follow 
clinic procedures to ensure confidentiality. 
•	 Clinics should have systems in place to assess 
and modify patient visits to assure minimal 
waiting. 
•	 The “expected-in” file should be checked for 
every person at every visit as part of the regis­
tration process. 
•	 Priority patients should be given preferential 
service. 
CLINIC FLOW 
Clinic flow should facilitate the effective use of per­
sonnel and physical facilities while preserving confi­
dentiality, dignity, and excellent medical care. Clinics 
should routinely evaluate space and financial resources 
critical to providing adequate services. The sequence 
of services should be logical so that confusion or un­
necessary delays for patients are avoided; emphasis 
should be placed on staff moving when necessary so 
that patients make as few moves as possible. Special 
stops (such as venipuncture or treatment) often be­
come a bottleneck. They tend to compromise efficient 
clinic operation with delays for patients because of 
the need for specialized staff, separate rooms, and sepa­
rate waiting areas. Individual clinicians can safely per­
form venipuncture in the examination room if they 
observe universal precautions. In any case, the initial 
patient visit should take no more than 1.5 hours from 
registration to treatment. (This does not include STD/ 
HIV interview sessions, partner services, or special cir­
cumstances which will vary in length depending on 
the STD diagnosis and individual patient needs.) 
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 Recommendations 
Appointment and Walk-in Systems 
•	 The responsibilities of the clinician will play a 
role in determining the number needed in a clinic. 
•	 Walk-in patients with genital ulcers, discharges, 
and women with abdominal pain or who are 
pregnant should be examined that day. 
•	 Patients referred by DIS should be seen on a 
priority basis on the same day. 
•	 Walk-in patients who are not examined within 
the day should be given a list of STD medical 
resources and eligibility requirements (e.g., 
urgent care clinics, family planning clinics, 
private physicians) and encouraged to call for 
a next-session appointment. 
Clinic Flow 
•	 Clinic flow should be designed so that the next 
available clinician sees the next patient regis­
tered. An exception may be made where local 
medical practice standards or legislation stipu­
lates gender requirements. Patients who re­
quest a clinician of a specific sex should be 
accommodated whenever possible. 
•	 Patient stops should be kept to a minimum 
(ideally, not more than three—registration, 
clinical care, and an STD/HIV interviewing/ 
counseling session, if needed). 
•	 Patient flow analysis should be conducted pe­
riodically to provide a systematic understand­
ing of where bottlenecks in clinic flow occur. 
MEDICAL RECORDS 
The format, composition, and maintenance of medi­
cal records are crucial. Review of the medical records 
can determine whether the records are properly main­
tained and documented, as well as whether clinicians 
are consistently following established protocols, thus 
ensuring high quality care for patients. Clinics that 
provide testing, treatment, and other early interven­
tion services for HIV infection will need to collect ad­
ditional information. Additional information on medi­
cal records should include HIV risk assessment, drug 
use, relevant sexual history, contraceptive use, con­
dom use, recent travel outside the U.S., hepatitis B 
vaccination history, whether counseling was provided, 
and plans for follow-up or referral. In areas of high 
HIV prevalence, additional information may be in­
cluded such as history of tuberculosis (including ex­
posure and infection). 
It is important that medical records contain suffi­
cient demographic information to identify and locate 
patients promptly and contain accurate information 
on symptoms, medical history, physical examination 
findings, laboratory tests, diagnoses, and treatment. 
Brief narrative descriptions should accompany items 
needing additional explanation or to document other 
relevant information. 
Medical records contain important and confiden­
tial information. They should be stored in locked files 
or locked rooms that are easily accessible to clinic per­
sonnel but inaccessible to unauthorized persons. It is 
important that medical records that are related to cases 
being managed by DIS be readily accessible to the DIS. 
Medical records should be removed from desk tops 
and filed in locked desk or file drawers at the end of 
each day. Computerized medical records also need to 
have rigorous access protection procedures to prevent 
unauthorized entry into the file, as well as back-up 
filing to prevent the loss of information. 
Recommendations 
•	 Medical records should contain sufficient de­
mographic information to contact the patient 
and sufficient clinical evaluation information 
to readily interpret the examining clinician’s 
assessment and clinical findings. 
•	 All procedures concerning content and filing 
of medical records should be in accordance 
with state and local laws and statutes. 
•	 STD programs should follow written proce­
dures for the management of medical records 
that includes forms management, organization 
of the medical record, records security, and 
adherence to statutes for record retention. 
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Recommendations, continued 
•	 An individual should be assigned the respon­
sibility of managing the release of records due 
to subpoena, court order, etc. This person 
should track all matters relating to the request 
to view medical records. 
CLINIC MANAGEMENT STRUCTURE 
Clinics should have one person (usually the clinic man­
ager) who has the authority to develop and implement 
clinic goals, policies, and procedures, as well as to 
manage personnel, orchestrate all clinic functions, and 
ensure quality of care. Delegation of clinic manager 
functions depends on clinic resources, staffing, and 
space. Working as part of the clinic management team, 
the medical director supports and complements the 
efforts of the clinic manager by carrying out a number 
of special medical duties. The interrelationship between 
management staff members (clinic manager, medical 
director, laboratory director, DIS supervisor, and other 
supervisory staff members) is critical to accomplish­
ing STD prevention program objectives. 
Clinic Manager 
At a minimum, job qualifications for clinic manager 
should include: 1) adequate medical knowledge to 
make valid comparisons between observed clinician 
performance and clinic protocols, 2) specialized STD 
training (see Clinician Performance Standards), 3) 
clinic management training, 4) public health experi­
ence or an orientation toward STD intervention con­
cepts and activities to understand the needs of DIS 
supervisors and staff, and 5) understanding of stan­
dard laboratory procedures and methods to coordi­
nate clinical and laboratory functions effectively. 
The clinic manager needs to have the necessary 
training and authority to carry out various personnel 
management responsibilities. These include: 1) devel­
opment of accurate job descriptions and reasonable 
performance standards for clinicians, 2) providing staff 
orientation, familiarity with work plans, and knowl­
edge of performance expectations, 3) arranging for 
adequate staffing to care for the patient population 
(even when vacations are scheduled), and assuring staff 
training and updates in STD patient management and 
universal precautions. 
The clinic manager also ensures that 1) clinic poli­
cies and procedures for all aspects of clinic operations 
are developed, implemented, and updated, 2) the clinic 
manual is current and accessible to all employees, vis­
iting clinicians, and clinicians-in-training, 3) informa­
tion is communicated to all staff through regular staff 
meetings and that staff members are encouraged to 
make suggestions about policies, 4) standard blood 
and body fluid precautions are observed by all per­
sonnel, 5) patient flow is optimal including develop­
ing policies for triage, quality assurance procedures 
for the clinical aspects are implemented and main­
tained, 7) the clinic facility, including  equipment and 
supplies, is adequate for the patient population, 8) that 
appropriate medical oversight is available as needed, 
9) quality assurance functions related to clinic opera­
tions are performed at regular intervals and the re­
sults are used to modify operations manuals . 
Medical Director 
The responsibilities of the medical director include: 
1) ensuring the best use of non-physician providers 
within the limits of state and local regulation, 2) sign­
ing standing orders for non-physician clinicians and 
acting as the final authority on medical care in the 
clinic, 3) being available, or arranging for other phy­
sician coverage in the director’s absence, for consulta­
tion with non-physician clinicians during all clinic 
hours, 4) identifying and assisting with the training of 
clinicians to improve clinical practice and learn new 
techniques, 5) assisting the clinic manager in clinician 
performance evaluations by observation and chart re­
views, 6) assuring that clinic manuals are up-to-date 
and appropriately used by the clinic manager to guide 
clinic activities, 7) routine auditing of medical records 
to ensure quality clinical care and that clinic proto­
cols are followed, 8) ensuring that the quality assur­
ance committee’s recommendations concerning medi­
cal care are implemented, 9) seeing patients in the STD 
clinic on a routine basis. 
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Recommendations 
•	 The clinic manager should have adequate spe­
cialized training in STD, clinic and person­
nel management, and public health. 
•	 The medical director should have specialized 
training in STD, be available for consultation 
during clinic hours and ensure the overall qual­
ity of clinical services. 
CLINIC MANUALS 
Clinic manuals should include all policies and proce­
dures that relate to the operation of the clinic. This 
should include personnel policies and medical proto­
cols that are followed in the local area, as well as any 
emergency or injury protocols. Current and signed stand­
ing orders for non-physician clinicians should be included 
if required or not prohibited by state laws and regula­
tions (medical practice acts). Standing orders are the 
signed instructions of a licensed physician which outline 
the medical assessment, appropriate testing, and treat­
ment that a clinician may perform or deliver on behalf of 
the physician. In some states, non-physicians are autho­
rized to perform assessments and prescribe medica­
tions independently. Standing orders also serve to stan­
dardize the clinical care practiced by all clinicians. 
Recommendations 
Personnel Policies 
•	 A STD clinic manual should contain the goals 
and the objectives of the clinic, including fully 
integrated STD/HIV services. 
•	 Job descriptions and performance standards 
should be provided for all staff members. 
These descriptions and standards should in­
clude: 
1. qualifications and training requirements for 
each job; 
2. the role each job plays in the operation of 
the clinic; 
3. a description of the essential tasks required 
for each job; 
Recommendations, continued 
4. the mechanism for performance evaluation; 
and 
5. attitudes expected to be conveyed to clinic 
patients. 
•	 Policies regarding employee health (e.g., in­
jury surveillance, HIV exposure, tuberculosis 
screening, and hepatitis B vaccination) should 
be consistent with state and local employee 
health regulations and should be clearly writ­
ten and enforced. 
•	 Procedures for formal quality assurance 
should be provided. 
•	 Local policies and procedures included in the 
manual (frequency of staff meetings, fire drill 
instructions, sick leave, and vacation) should 
be current. 
Medical Protocols 
•	 Clinic protocols or standard medical instruc­
tions for specific patient management should 
include: 
1. patient evaluation; 
2. management of STDs (See CDC STD Treat­
ment Guidelines); 
3. medical consultation and referral; 
4. follow-up after therapy; 
5. counseling/education; 
6. and management of sex partners. 
•	 Protocols should include current recom­
mended treatments for STDs. 
•	 Emergency medical protocols should be cur­
rent. 
•	 Protocols for the safe handling of blood and 
body fluids (standard precautions) should be 
current and practical for most clinic situations. 
•	 Current and signed standing orders for non-
physician clinicians should be included if re­
quired or not prohibited by state laws and 
regulations (medical practice acts). 
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CLINICIAN ROLES AND PERFORMANCE 
STANDARDS 
The use of non-physician clinicians is critical to STD 
medical management. Non-physician clinicians can 
manage most STDs and can provide HIV prevention 
counseling. Nursing and physician assistant roles 
should not be limited to history taking, assisting phy­
sicians, and dispensing medication. Having a single 
clinician manage each patient lessens the patient’s sense 
of fragmentation and impersonal interaction; it also 
improves patient flow and patient satisfaction. Patients’ 
perceptions and experiences during the examination 
can influence their willingness to comply with staff 
instructions at any step in the process. The extent to 
which various categories of non-physicians can func­
tion as clinicians is defined in medical practice stat­
utes and legal precedent in each state or locality. Cli­
nicians who perform HIV prevention counseling or 
partner services should receive specific skill training 
and should be evaluated regularly in those skills. 
At a minimum a clinician must have the appropri­
ate licensure or credentials required by the state or 
locality. New clinicians should have a preceptorship 
before caring for patients independently. Specific train­
ing for clinicians inexperienced in STD examinations 
should include completion of the Comprehensive or 
Intensive STD Clinician Course at a STD/HIV Preven­
tion/Training Center or a similar course; completion 
of an AIDS Update Course, or equivalent, that includes 
clinical and epidemiologic information about HIV 
infection; a course in HIV client centered counseling, 
if this service is a clinical care responsibility; and cer­
tification or special training in Mantoux skin testing 
for tuberculosis (when testing is provided in the 
clinic). 
The manner in which clinicians relate to patients, 
especially in a STD clinic, is critical to patient accep­
tance and follow through on treatment, behavioral 
intervention, and prevention of transmission to oth­
ers. Clinicians should present an image of sensitivity 
and competence to the patient. The importance of good 
interviewing, counseling, and education skills on the 
part of the clinician cannot be overstated. All relevant 
medical history, risk assessment, examination, diag­
nosis, and treatment should be accurate and noted in 
the medical record. Counseling messages should be 
specific, clear, and allow the patient time to ask ques­
tions. Clinicians should strictly adhere to standard (for­
merly known as universal blood and body fluid stan­
dards) precautions. Clinicians should facilitate a 
seamless transfer of the case to other team members 
such as DIS when appropriate. 
Recommendations 
•	 Nurses, nurse practitioners, and physician as­
sistants should work in full compliance with 
established clinic protocols as clinicians re­
sponsible for the entire clinical care process, 
including history taking, physical examina­
tion, laboratory specimen collection, diagno­
sis, treatment, plan for follow-up, and coun­
seling/education. 
•	 Non-physician clinicians should have ad­
equate physician backup and specific stand­
ing orders. 
•	 All clinicians should have a specific STD train­
ing course and AIDS update course. 
STANDARD PRECAUTIONS 
Standard Precautions are a set of protocols designed 
to reduce the risk of (or prevent) transmission of patho­
gens. Standard precautions synthesize the major fea­
tures of Universal (Blood and Body Fluid) Precautions 
(designed to reduce the risk of transmission of 
bloodborne pathogens) and Body Substance Isolation 
(designed to reduce the risk of transmission of patho­
gens from moist body substances). Under standard 
precautions blood, all body fluids, and all body sub­
stances of patients are considered potentially infectious 
(CDC, 1997). 
Standard precautions should be observed by all clini­
cal personnel for all patients as part of routine infec­
tion control. Clinicians, laboratory technicians, phle­
botomists, and other health care professionals routinely 
come into contact with blood and body fluids during 
the course of examination and testing. Blood is the 
single most important source of infection with HIV 
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and viral hepatitis in the workplace. The potential for 
hepatitis transmission in the clinic is greater than for 
HIV. Health care workers should be particularly alert 
to the need for preventing tuberculosis transmission 
in settings in which persons with HIV infection re­
ceive care. 
Federal regulations on preventing the spread of 
bloodborne pathogens are contained in the final rule 
(Department of Labor, Occupational Safety and Health 
Administration, Occupational exposure to bloodborne 
pathogens; final rule (29 CER 1910.1030) Federal 
Register, pp. 64004-64182, Dec. 6, 1991.)  These regu­
lations, which took effect on March 6, 1992, outline 
in detail what employees must be taught about the 
hazards of working with potentially infectious mate­
rials and what precautions must be taken to prevent 
or minimize exposure to such materials. The regula­
tions are summarized below. 
•	 Every employer is required to have a written expo­
sure control plan designed to eliminate or minimize 
worker exposure. The document must include all 
job classifications and job tasks in that place of em­
ployment that could lead to occupational exposure 
and the names of workers at risk for exposure to 
infectious materials. The written exposure control 
plan must have a record keeping element that in­
cludes a training records section and a medical 
records section. 
•	 Training records must include the date, content 
outline, trainer’s name and qualifications, and 
names and job titles of all persons attending the 
training sessions. 
•	 A medical record must be established for each em­
ployee with occupational exposure. This record is 
confidential and separate from other personnel 
records. The medical record contains the employee’s 
name, social security number, hepatitis B vaccina­
tion status, including the dates of vaccination and 
the written opinion of the health care professional 
regarding the Hepatitis B vaccination. If an occu­
pational exposure occurs, reports are added to the 
medical record to document the incident and the 
results of testing following the incident. 
•Any employee whose job requires contact with 
blood or other body fluids must receive free 
biosafety training during working hours, followed 
by annual refresher courses. 
•	 All workers to whom standard precautions apply 
should be offered and should strongly consider re­
ceiving hepatitis B vaccine. 
•	 Each clinic in which persons with HIV infection 
receive care should have a policy for Mantoux tu­
berculin skin testing of all health care facility work­
ers (not just those interacting with patients). A 
baseline skin test administered within 2 weeks of 
employment and a follow-up based on the preva­
lence of tuberculosis in the patient population and 
community is suggested. 
Recommendations 
•	 Standard Precautions should be applied to (1) 
blood; (2) all body fluids, secretions, and ex­
cretions, except sweat, regardless of whether 
or not they contain visible blood; (3) broken 
skin; and (4) mucous membranes. Standard 
Precautions are designed to reduce the risk of 
transmission of microorganisms from both 
recognized and unrecognized sources of infec­
tion in health care settings. 
•	 Protective barriers should be appropriate and 
available for the type of exposure anticipated 
and may include latex or vinyl examination 
gloves, gowns, masks, and protective eye wear. 
•	 Needles and syringes should not be recapped 
or removed from disposable syringes. 
•	 Disposable syringes and other sharp items 
should be placed in puncture-resistant contain­
ers located in the immediate vicinity where 
venipuncture procedures take place. 
•	 Gloves should be worn during venipuncture 
to reduce the incidence of blood contamina­
tion, recognizing that they cannot prevent 
needle-stick injuries. 
•	 Clinicians and phlebotomists should change 
gloves between patients. 
•	 Gloves should not be worn outside the exami­
nation room or the laboratory. 
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Recommendations, continued 
•	 Skin on hands or other parts of the body 
should be immediately and thoroughly washed 
if contaminated with blood or other body flu­
ids. Hands should always be washed before 
and after the examination and before leaving 
the examination room. 
•	 Infectious waste should be incinerated or au­
toclaved before disposal in a sanitary landfill. 
•	 A surveillance system should be established 
for injuries such as needle-sticks, percutane­
ous injuries, and mucous membrane contami­
nation; protocols should specify collection of 
confidential information about the worker and 
about the source individual (if applicable and 
possible), and about the cause and type of in­
jury, medical treatment, counseling, and fol­
low-up. 
EMERGENCY PROCEDURES 
STD clinics should be prepared for medical emergen­
cies, particularly life-threatening drug reactions of 
patients and occupational exposures that may place 
health care workers at risk for acquiring any 
bloodborne infections, including HIV. Each clinic 
should have established procedures, adequate and 
properly maintained equipment, and appropriately 
trained staff. Each clinic should have a written proto­
col for prompt reporting, evaluation, counseling, treat­
ment, and follow up of occupational exposures (CDC, 
1998). 
Recommendations 
•	 One copy of an emergency protocol should 
be kept in the clinic manual and one copy with 
the emergency supplies. 
•	 Emergency equipment, supplies, and medica­
tions should be updated frequently according 
to an established schedule to ensure that they 
are not depleted or expired. Emergency sup­
plies should be sealed when not in use. 
Recommendations, continued 
•	 All clinical staff members should be trained 
in cardiopulmonary resuscitation and should 
be able to respond appropriately in an emer­
gency. 
•	 Staff members should be trained in specific 
safety procedures for managing potentially 
violent or abusive persons in the clinic. 
•	 Mock emergency drills should be held at least 
twice yearly to ensure that all staff members 
recognize emergencies, know their roles and 
responsibilities, know the location and con­
tents of emergency supplies, can use all equip­
ment properly, and follow established proto­
cols. 
•	 STD prevention programs should develop and 
implement policies and procedures to man­
age occupational exposures of health care 
workers. 
STAT LABORATORY MANAGEMENT 
STRUCTURE 
An on-site laboratory prepared to perform immediate 
(stat), high quality testing to assist with the diagnosis 
of various STDs is an indispensable component of any 
STD clinic. Results of stat tests should be given to the 
patient during the clinic visit. Links should be estab­
lished or maintained with reference laboratories for 
nonroutine or special testing to provide comprehen­
sive coverage for clinical services. For information on 
commonly used stat tests, see Appendices ML-B 
through ML-E. All laboratories must comply with state 
and federal regulations governing diagnostic testing. 
The laboratory director may be on site or at the state 
or local health department for laboratories that have 
the exemption for limited public health testing (see 
Appendix ML-A). 
The use of point-of-care tests can have significant 
treatment and economic benefit in populations in 
which follow-up treatment rates are relatively low. 
How much benefit they have relative to the use of other 
tests depends upon their performance characteristics 
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and cost, and the notification and treatment rates that 
would occur if other tests were used. 
Some laboratories take advantage of the relative 
performance simplicity of the point-of-care tests and 
“batch” tests from individual patients together, per­
forming them after the patient has left. The perfor­
mance characteristics of point-of-care tests are often 
not as good as other tests, lessening their comparative 
advantage. In such instances as these, use of the tests 
is justified only when positive results are available to 
permit diagnosis of patients at the time of their visit. 
Clinic laboratorians should have access to a 
brightfield microscope. In addition, laboratorians in 
those clinics where rapid syphilis diagnosis is impor­
tant, should have available at least one darkfield mi­
croscope, or the ability to convert a brightfield micro­
scope for use as a darkfield microscope. There is a 
need for additional darkfield microscopes in areas with 
greater prevalence of genital ulcer disease. 
Recommendations 
Laboratory Direction 
•	 The laboratory director should be trained in 
appropriate laboratory techniques and safety 
procedures associated with handling infectious 
agents. 
•	 The director should have experience in public 
health and an understanding of the needs of 
clinicians and DIS staff. 
•	 Optimal qualifications of the laboratory di­
rector include a doctoral degree in medicine 
or laboratory science (see Appendix ML-A). 
•	 The director should ensure that the quality as­
surance committee’s recommendations for 
laboratory testing are implemented. 
•	 The laboratory director may be on site or at 
the state or local health department for labo­
ratories that have the exemption for limited 
public health testing. 
•	 Staff members should be familiar with work 
plans and should receive periodic performance 
evaluations. 
Recommendations, continued 
•	 Only personnel who have been advised of po­
tential hazards and who meet specific require­
ments should be allowed to enter the labora­
tory. 
•	 The director should ensure adequate staffing 
to manage the volume of rapid testing during 
peak testing hours, lunch, and employee va­
cations. 
•	 Accurate and updated test procedures and 
biosafety manuals should be available to all 
laboratory employees. 
•	 Policies should be established to ensure the 
confidential storage of laboratory requisitions 
or log books containing patients’ test results. 
Confidentiality statutes in each jurisdiction 
define the records that are protected from sub­
poena and may specify the time frame for re­
tention and the method for destruction. 
Laboratory Services 
•	 Each clinic that provides STD services should 
have an on-site stat laboratory or capacity to 
perform stat tests. The laboratory must have 
a current CLIA certificate and be in compli­
ance with CLIA-88 (see Appendix ML-A). 
•	 At a minimum, stat laboratories should per­
form the following tests, all of which are clas­
sified as of moderate complexity under CLIA, 
with the exception of urine pregnancy tests, 
which are classified as waived under CLIA: 
1. Gram stain to detect intracellular gram-
negative diplococci and presence of white 
blood cells to detect cervicitis or urethritis 
2. nontreponemal antibody card tests for 
syphilis such as RPR, TRUST, RST 
3. darkfield examination for 	Treponema 
pallidum 
4. saline wet mount for Trichomonas vaginalis 
and detection of clue cells of bacterial 
vaginosis 
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Recommendations, continued 
5. KOH wet mount for the identification of 
yeast and for amine odor (Whiff) test 
6. Urine pregnancy tests 
•	 Point-of-care tests should only be used to pro­
vide immediate results and treatment to pa­
tients. If testing does not occur immediately, 
tests with greater sensitivity and specificity 
should be used. 
•	 The stat laboratory should contain an appro­
priate number of brightfield and darkfield 
microscopes and adequate equipment, sup­
plies, and reagents to process patient speci­
mens rapidly. 
•	 A sufficient number of staff should be trained 
in darkfield microscopy to provide coverage 
during all clinic hours where rapid syphilis 
diagnosis is desirable. 
•	 The stat laboratory should send the follow­
ing routine tests to the state health laboratory 
or other non-stat laboratory: 
1. presumptive and confirmatory identifica­
tion and antimicrobial sensitivity tests for 
N. gonorrhoeae; [presumptive- moderate 
complexity; confirmatory and sensitivity 
tests-high complexity-CLIA] 
2. chlamydia diagnostic tests (most high com­
plexity—CLIA) 
3. nontreponemal antibody tests for syphilis 
(VDRL—high complexity, RPR and other 
similar card tests—moderate complexity— 
CLIA ) 
4. fluorescent treponemal antibody absorp­
tion (FTA-ABS) or other treponemal tests 
for syphilis [high complexity—CLIA]; and 
5. HIV antibody tests [moderate complexity-
CLIA, many others, high complexity-CLIA] 
•	 Additional stat testing may include; 
1. Tzanck stain for herpes [moderate-CLIA] 
2. spun urine for Gram stain and white cell 
count [moderate-CLIA] 
Recommendations, continued 
•	 STD clinics should use routine and reference 
laboratory services which further facilitate the 
diagnosis of STDs. 
LABORATORIAN ROLES AND 
PERFORMANCE STANDARDS 
Quality stat laboratory testing by trained personnel 
contributes to rapid diagnosis and efficient clinic flow. 
Laboratory testing is inherently amenable to objective, 
continuing methods of quality assurance. Federal regu­
lations stipulate the professional training needed to 
conduct laboratory tests. The employment of person­
nel failing to meet the professional training require­
ments mandated by federal regulations governing di­
agnostic testing may place persons and facilities in 
jeopardy of legal prosecution. 
Recommendations 
•	 Job qualifications for laboratorians include (at 
a minimum) high school graduation and train­
ing received at a medical or technical school; 
certification as a laboratory technician or tech­
nologist, professional registration as a micro­
biologist, or a degree in biological science; and, 
courses in basic stat laboratory methods for 
STD testing (brightfield and darkfield micros­
copy, gonorrhea culturing, rapid chlamydia 
tests, and syphilis serology) at one of the STD 
Prevention/Training Centers, or similar train­
ing. 
•	 All laboratory workers should routinely par­
ticipate in proficiency testing. 
•	 A laboratory worker should possess a profes­
sional attitude and sensitivity about confiden­
tiality; this includes not discussing laboratory 
results within patients’ hearing. 
•	 A laboratory worker should adhere strictly to 
universal precautions, safety procedures, and 
quality control procedures. 
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LABORATORY BIOSAFETY LEVEL Recommendations, continued 
CRITERIA 
Biosafety levels consist of combinations of laboratory 
practices and techniques, safety equipment, and labo­
ratory facilities appropriate for the operations per­
formed, the hazard posed by the infectious agents, and 
for the laboratory functions or activities. STD stat labo­
ratories fall under Biosafety Level 2. This means that 
the laboratory is suitable for work involving agents of 
moderate potential hazard to personnel and the envi­
ronment, laboratory personnel have specific training 
in handling pathogenic agents and are directed by com­
petent scientists, access to the laboratory is limited 
when work is being conducted, extreme precautions 
are taken with contaminated sharp items, and proce­
dures in which infectious aerosols or splashes may be 
created are conducted in biological safety cabinets or 
other physical containment equipment. 
Recommendations 
Microbiological Procedures 
•	 Access to the laboratory should be limited to 
appropriate personnel and should be restricted 
when work with infectious agents is in 
progress. 
•	 Work surfaces should be decontaminated 
daily, as well as immediately after a spill. 
•	 All infectious waste should be decontaminated 
before disposal. 
•	 Mouth pipetting is prohibited; mechanical 
pipetting devices are used. 
•	 Eating, drinking, smoking, handling contact 
lenses, and applying cosmetics are not permit­
ted in the work areas. Contact lens wearers in 
laboratories should also wear goggles or a face 
shield. Food is stored in cabinets or refrigera­
tors designated for that purpose only, outside 
the work area. 
•	 Thorough hand washing should be performed 
after handling infectious materials and before 
leaving the laboratory. 
•	 Procedures to minimize the creation of 
splashes or aerosols should be followed. 
•	 An insect and rodent control program should 
be in effect. 
•	 Universal biohazard symbols should be posted 
on the laboratory door. 
•	 Laboratory personnel should receive appro­
priate immunizations or screening for the 
agent handled or potentially present in the 
laboratory (e.g., hepatitis B vaccine or TB skin 
testing). 
•	 Baseline serum samples for laboratory and 
other at-risk personnel should be collected and 
stored, when appropriate, considering the 
agent(s) handled. Additional serum specimens 
may be collected periodically. 
•	 A biosafety manual should be prepared or 
adopted. Personnel should be advised of spe­
cial hazards and should be required to read 
and follow instructions on practices and pro­
cedures. 
•	 Contaminated sharp items, including needles 
and syringes, should be promptly placed in 
puncture- proof containers for decontamina­
tion. 
•	 Laboratory personnel should receive appro­
priate training on the potential hazards asso­
ciated with the work involved, the necessary 
precautions to prevent exposures, and expo­
sure evaluation procedures. Personnel should 
receive periodic updates, or as necessary. 
•	 Cultures, tissues, or specimens of body fluids 
should be placed in a container that prevents 
leakage during collection, handling, process­
ing, storage, transport, or shipping. 
•	 Laboratory equipment and work surfaces 
should be decontaminated with an appropri­
ate disinfectant on a routine basis after work 
with infectious materials is finished, and es­
pecially after spills. 
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Recommendations, continued 
•	 Spills and accidents which result in overt ex­
posures to infectious materials should be re­
ported to the laboratory director immediately.
 Safety Equipment (Primary Barriers) 
•	 Biological safety cabinets, or other appropri­
ate protective equipment should be used when 
procedures with a potential for creating in­
fectious aerosols or splash are conducted, or 
high concentrations or large volumes of in­
fectious agents are used. 
•	 Face protection (goggles, mask, face shield or 
other splatter guards) should be used for an­
ticipated splashes or sprays of infectious ma­
terials. 
•	 Protective laboratory coats, gowns, smocks, 
or uniforms designated for lab use should be 
removed and left in the laboratory before leav­
ing for non-laboratory areas. 
•	 Examination gloves should be worn when 
handling infectious materials, contaminated 
surfaces or equipment. Gloves should be dis­
posed of when contaminated, or when work 
with infectious materials is completed. Dis­
posable gloves should not be washed or re­
used. 
Laboratory Facilities (Secondary Barriers) 
•	 Each laboratory should contain a sink for 
washing hands. 
•	 The laboratory should be designed for easy 
cleaning. 
•	 Bench tops should be impervious to water and 
resistant to acids, alkalis, organic solvents, 
and moderate heat. 
•	 Furniture in the laboratory should be sturdy, 
with spaces between benches, cabinets, and 
equipment accessible for cleaning. 
•	 If the laboratory has windows that open, they 
should be fitted with fly screens. 
Recommendations, continued 
•	 A method for decontamination of infectious 
or regulated laboratory wastes should be avail­
able (e.g., autoclave, chemical disinfection, 
incinerator, or other approved decontamina­
tion system). 
•	 An eyewash facility should be readily avail­
able. 
LABORATORY PRACTICE AND 
TECHNIQUES 
Basic stat laboratories should adhere to the recom­
mended practices and techniques for a Biosafety Level 
2 facility. The laboratory should be close to the ex­
amination rooms for easy access by clinicians who are 
transporting specimens; however, it should be sepa­
rated from public areas and general offices where non-
laboratory staff members require frequent access. Each 
facility should develop or adopt a biosafety manual. 
All staff responsible for performing laboratory testing 
should adhere to the recommended microbiological 
practices and follow approved procedures. 
Protocols for transport and storage of specimens 
should be established and followed. For example, 
blood specimens should be delivered to the labora­
tory for processing at the earliest practical time, avoid­
ing extended periods in a car or similar sitting where 
temperatures may become excessive. If blood speci­
mens cannot be delivered to the laboratory on the day 
of collection they should be stored upright in the re­
frigerator. Do not freeze, as hemolysis may occur, ru­
ining the specimen. For chlamydia testing, urine 
samples should be transported in an insulated trans­
port container rack to restrict movement and spillage. 
Ice packs to maintain a cold atmosphere must be used 
in the transport container. If urine samples cannot be 
delivered to the laboratory on the day of collection, 
samples must be frozen and delivered, without being al­
lowed to thaw, on the next day. Urine specimens stored 
at room temperature cannot be used for testing. 
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Recommendations 
Microbiological Practices 
•	 All procedures should be consistent with rec­
ognized standard and specialized microbio­
logic practices. 
•	 Biological safety cabinets, previously termed 
“hood,” (Class I or II) or other physical con­
tainment devices should be used during proce­
dures in which infectious aerosols may be cre­
ated. 
•	 Any activity with the potential for creating aero­
sols (e.g., centrifugation of blood) should be per­
formed in low-traffic areas in the laboratory. 
•	 All testing should be performed under quality 
assurance guidelines specific for each test (e.g., 
control specimens, temperature, time). 
•	 Safety equipment should include items for per­
sonal protection such as gloves, coats, face 
shields, and safety glasses. 
•	 Cultures, tissues, or specimens of body fluids 
should be placed in a container that prevents 
leakage during collection, handling, process­
ing, storage, transport, or shipping. Labora­
tory specimens should be placed in durable 
trays or containers for safe transport, even for 
short distances. 
Procedures Manual 
•	 The manual should include step-by-step descrip­
tions of all methods; modifications of procedures 
should be initialed by the laboratory director. 
•	 The manual should include criteria for labo­
ratory specimen acceptability. 
•	 Daily quality control records pertaining to test 
controls and to equipment, temperature, and 
speed of rotation should be noted in the 
manual. 
•	 Procedures for quality control checks on new 
lots of reagents, whether purchased or pre­
pared, should be noted in a special section. 
Recommendations, continued 
•	 Instructions for routine tests and special stud­
ies should be documented in the manual. 
Biosafety Manual 
•	 All new employees should read and under­
stand the biosafety manual before working in 
the laboratory. (See section, Standard Precau­
tions, for OSHA mandated training required 
for all employees who may have contact with 
blood or other body fluids.) 
•	 The manual should include information on 
standard and special microbiologic practices 
appropriate to laboratory Biosafety Level 2. 
•	 The biosafety manual should be regularly up­
dated. 
•	 Laboratory procedures should be reviewed for 
compliance with established safety practices 
by a safety proctor appointed by the labora­
tory director. 
PROVIDING STAT LABORATORY 
SERVICES IN COMPLIANCE WITH CLIA 
The Clinical Laboratory Improvement Amendments 
of 1988 (CLIA ‘88) are federal minimum quality stan­
dards for all laboratory testing. On February 28, 1992, 
regulations implementing CLIA were published in the 
Federal Register, Vol. 57, No. 40, February 28, 1992, 
Rules and Regulations, pp. 7137-7288. 
Tables summarizing the personnel requirements for 
moderate (including Provider Performed Microscopy) 
and high complexity laboratories are contained in 
Appendix ML-A, as well as instructions for obtaining 
a complete list of categorized test systems, a list of 
waived test systems from the Internet, and a brief his­
tory of CLIA. Appendix ML-A also discusses the op­
portunity for an exemption to the certification require­
ments for limited public health testing. 
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Recommendations 
•	 The exemption to the certification requirement 
for each location available for limited public 
health testing (LPHT) should be pursued, if 
feasible. The state public health laboratories 
may be the only facilities with the mandate, 
expertise, and infrastructure to facilitate labo­
ratory partnerships between large numbers of 
locally administered clinic laboratories. 
VENIPUNCTURE 
Venipuncture skills are desired and very often required 
of STD staff, including Disease Intervention Special­
ists (DIS). Venipuncture is often performed to obtain 
a blood specimen for STD/HIV testing. This is a safe 
procedure when performed correctly by individuals 
who have received proper training. Training and cer­
tification (if necessary) for proficiency in venipuncture 
is usually obtained by working with a licensed physi­
cian or other persons skilled in venipuncture. In many 
areas the STD staff may perform venipuncture only 
under a physician’s standing order and must adhere to 
all the stipulations outlined in the standing order. 
Observation and practice is required to become skilled 
and self-confident in the art of venipuncture. Several of 
the STD/HIV Prevention Training Centers (PTCs) offer 
training in venipuncture techniques. Other opportuni­
ties for training include on-the-job, one-on-one train­
ing in a clinical practicum with a health care worker 
properly qualified to train and certify (if necessary), 
or local private providers who can be contractors (e.g., 
Red Cross, blood banks, community colleges). The 
training provider may be a city or county clinic or 
health department, state health department, local hos­
pital, school of medical technology in a college or uni­
versity, or a Red Cross training program. A sample train­
ing program is included in Appendix ML-F. 
When performing venipuncture, the STD staff 
should always be aware that this procedure is being 
done under the legal authority of the local health of­
ficer. The staff must become familiar with the relevant 
legal authorities and adhere to the procedural require­
ments of the health department Laboratory Director. 
It is imperative that the staff exercise the utmost care 
and professional judgment in the application of veni­
puncture procedures. If a needle-stick injury occurs, 
the injured employee should immediately contact their 
supervisor and follow local health care worker occu­
pational exposure policies (see section on emergency 
procedures). In addition, for Federal employees, im­
mediate notification of the exposure should be pro­
vided to the CDC Office of Health and Safety. 
Venipuncture in the field (field bloods) is most com­
monly performed by DIS on members of identified 
groups at high risk of syphilis and HIV infection; part­
ners of known syphilis or HIV positive patients; asso­
ciates of known syphilis patients (including cluster 
suspects); and previously examined persons for whom 
a physician desires another serologic test only. Each 
program area should determine their priorities for field 
bloods. 
Professional judgement may compel the DIS to draw 
a blood specimen from an individual who clearly is in 
need of clinical evaluation or treatment. It would be 
prudent for the DIS to extract a specimen when the 
opportunity presents itself, if it appears the individual 
is deemed unreliable or expresses reluctance to accept 
medical services. Such applications of field venipunc­
ture must be considered judiciously and in context with 
local policies. When these situations arise, the DIS must 
report such activities to the supervisor at the earliest 
opportunity. 
Recommendations 
•	 A continuing Quality Assurance program 
should be in place to monitor the venipunc­
ture performance of STD staff. 
•	 The DIS supervisor should closely monitor DIS 
until assured that their venipuncture perfor­
mance is satisfactory. 
•	 Periodic monitoring should continue after the 
initial observation period. See Appendix ML­
F for an example of a venipuncture evalua­
tion tool. 
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•	 When labeling and transporting specimens, the 
DIS should: 
•	 Print the patient’s name and date of birth 
(if known) or place a pre-printed label on 
the specimen tube after the blood has been 
collected. Include the date the specimen was 
drawn. To prevent the incorrect labeling of 
blood specimens do not pre-label blood col­
lection tubes. 
•	 Maintain blood specimens in an upright po­
sition with the stopper at the top, either by 
placing in a specimen rack or in a card­
board container. Pack the containers tightly 
so the specimens will be secure in transit. 
•	 Blood specimens should be delivered to the 
laboratory for processing at the earliest 
practical time. Avoid leaving for extended 
periods in a car or similar place where tem­
peratures may become excessively high or 
low. Also, make sure specimens remain in 
your care and that they are not handled by 
unauthorized persons. 
•	 When blood specimens cannot be delivered 
to the laboratory on the day of collection, 
make sure they are stored upright in a re­
frigerator. Do not freeze, as hemolysis may 
occur, ruining the specimen. 
DISEASE INTERVENTION SPECIALIST 
SERVICES IN MEDICAL FACILITIES 
The work performed by disease intervention special­
ists (DIS) is essential to the successful operation of a 
STD clinic. DIS reinforce the education and counsel­
ing messages provided by the STD clinician during the 
examination. More importantly, they interview and 
counsel patients and perform investigations to locate 
people who may be at risk for STD and refer them for 
examination, treatment, and counseling (see the chap­
ter on partner services for more detail on DIS activi­
ties outside the clinic). It is appropriate for the DIS to 
offer a full range of intervention services in a single 
session rather than ask a patient to repeat the same 
information to several people. Because STD-related 
information is sensitive, the patient’s transition between 
clinical care and the STD interview or HIV prevention 
counseling session must be smooth and appear to be 
natural extensions of each other. 
Recommendations 
•	 Consistent prevention messages to patients 
should be facilitated through regular commu­
nication between clinic providers and DIS. 
•	 Clinic procedures should promote a smooth 
and confidential exchange of relevant disease 
intervention information between clinical staff 
and DIS. 
•	 DIS should be on site or on call to provide 
disease intervention services during clinic 
hours. Where resources are lacking for spe­
cialized disease intervention staff, or work is 
reassigned based on disease priorities, clini­
cians and counselors can perform intervention 
services. 
•	 DIS should have a thorough understanding of 
STD clinical care and STD diagnostic test re­
sults. 
•	 Clinic protocols should specify which patients 
are to receive STD and HIV intervention ser­
vices from DIS. 
•	 DIS should be provided with an adequate 
number of private rooms to ensure that con­
fidential STD interviews and HIV prevention 
counseling sessions can be conducted without 
interruption. 
•	 All personnel should be evaluated for STD in­
tervention and HIV test counseling skills to 
assure consistency of messages. 
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QUALITY ASSURANCE PROCEDURES 
Quality assurance activities and programs within clin­
ics are important functions that ensure a minimal stan­
dard of acceptable clinical care, clinic management, 
and clinic operations. A well designed quality assur­
ance program provides opportunity for clinic person­
nel from diverse areas to interact in the process of ob­
jectively reviewing clinical, management, and 
operations outcomes. The results of quality assurance 
activities should be used to modify clinic policy and 
procedures in an effort to improve clinical care, clinic 
management, and/or clinic operations. 
Recommendations 
•	 A quality assurance committee should meet 
regularly and follow an approved protocol to 
conduct audits, analyze findings, and deliver 
recommendations. 
•	 Medical records should be audited regularly 
(checked against clinic protocols) to determine 
the appropriateness of diagnoses and treat­
ment and the completeness of documentation. 
•	 The quality of stat laboratory procedures 
should be monitored regularly. 
•	 Staff interactions with patients should be ob­
served regularly. 
•	 Semiannual safety audits should be performed 
to determine the appropriate use of electrical 
equipment, storage of chemicals, emergency 
procedures, and first-aid stations. 
•	 A mechanism should be established for receiv­
ing, reviewing, and responding to complaints 
of patients. 
•	 Representatives of the finance office and data 
processing unit should also be included on the 
quality assurance committee so that they can 
gain and maintain an understanding of clinic 
operational needs. 
REPORTING 
Morbidity 
Epidemiologic surveillance is the continuing and sys­
tematic collection, analysis, and interpretation of 
health data in the process of describing and monitor­
ing a health event. Surveillance reporting permits a 
program to fulfill its mandated function of informing 
the public about a health problem, and facilitates ba­
sic program planning, implementation, and evaluation 
to determine public health action. State law specifies 
which diseases to report and which practitioner or fa­
cility is responsible for reporting diseases and situa­
tions (e.g., child abuse) to the official state agency. 
Reportable STDs mandated by state laws and included 
in federal and other voluntary surveillance systems 
usually include cases of gonorrhea, chlamydia, syphi­
lis, chancroid, lymphogranuloma venereum, and 
granuloma inguinale. Some states also require report­
ing of HIV, PID, or genital herpes. Uniform STD sur­
veillance case definitions are vital to the management 
of disease prevention programs. Case definitions may 
differ from diagnostic criteria meant to assist the cli­
nician in arriving at a certainty of diagnosis for a given 
patient and disease. (See Surveillance and Data Man­
agement for further information.) 
Sexual Abuse and Assault 
The management of STDs in children and the suspected 
sexual abuse of children requires close cooperation 
between clinic personnel and child protection authori­
ties. Some diseases, such as gonorrhea and syphilis are 
virtually 100% indicative of sexual contact if diag­
nosed in children after the neonatal period. The asso­
ciation of other STDs in children and the occurrence 
of child sexual abuse is not definitive. Most STD clinic 
personnel lack experience in the management of sus­
pected child sexual abuse evaluations. Suspected vic­
tims of child sexual assault or abuse should be exam­
ined by a provider trained and/or certified to do such 
evaluations. Alternatively, suspected victims can be 
referred to an Emergency Department where trained 
clinicians are on call 24 hours/day. Clinic protocols 
should address referral policy and clinic staff should 
facilitate a referral, if necessary, in a manner that mini­
mizes the victim’s discomfort and anxiety. 
ML – 18	 Program Operations Guidelines for STD Prevention 
 
 
 
Domestic Violence 
The US Department of Justice estimates that 55% of 
women are raped and/or physically assaulted during 
their lifetime.(U.S. Department of Justice, 1998) 
Overall, estimates of numbers of women who experi­
ence abuse annually in the United States range from 8 
to 12 percent. (Wilt, 1996)  Many believe that these 
estimates are low. Victims and their abusers, more of­
ten than not, know each other and frequently live in 
the same household. The term domestic violence gen­
erally refers to violence and abuse within the home 
but also includes violence and/or abuse between people 
who know each other regardless of where the abusive 
event(s) takes place. Physical violence and abuse is only 
one method that an abuser may utilize to maintain 
control over the victim. Other abuse tactics include 
emotional and verbal abuse, isolation, and threats and 
intimidation. (U. S. Department of Justice, Website)  Risk 
factors for domestic violence and abuse, such as young 
age, and drug and alcohol abuse are frequently the 
same as those for having a STD. This suggests, at least, 
that screening for domestic violence and abuse in ven­
ues where there is screening and treatment for STDs 
would lead to the identification of  intervention oppor­
tunities for what is a universal health care problem. 
The federal Violence Against Women Act, passed 
as part of the Violent Crime Control Law Enforce­
ment Act of 1994, established the National Domestic 
Violence Hotline. This nationwide, toll free hotline 
serves victims of domestic violence by providing local 
referral information. The hotline can be reached by 
dialing 1-800-799-SAFE or 1- 800-787-3224 (TDD). 
A Community Checklist: Important Steps to End 
Violence Against Women, (Department of Justice, 
1995) identified several strategies that health care pro­
fessionals can employ to intervene effectively into the 
problem of domestic violence in their communities and 
amongst their clients. These include: 
•	 Incorporate Training into Curricula 
•	 Make Resources Available to Patients 
•	 Support Incorporation of Protocols into Accredita­
tion Process 
•	 Encourage Continuing Education on Violence 
Against Women Issues 
•	 Involve Medical Organizations and Societies in In­
creasing Awareness 
•	 Feature Violence Against Women on Meeting Agen­
das 
•	 Highlight Commitment to Violence Against Women 
Issues 
•	 Develop a Standard Intake Form 
•	 Ensure Employee Assistance Programs are Respon­
sive to Victims of Domestic Violence 
•	 Volunteer in Community Organizations That Serve 
Victims of Domestic and Sexual Violence 
Recommendations 
Disease Morbidity 
•	 Clinics should promptly submit morbidity re­
ports following the diagnosis of a case in the 
format determined by the state or local pre­
vention program. 
•	 Morbidity reports should be complete, legible, 
and checked for accuracy before submission. 
•	 The quality assurance of morbidity reports 
should involve periodic comparison with 
medical records. 
•	 Computerized medical record systems should 
be linked to electronic morbidity reporting to 
expedite rapid data collection. 
•	 Clinic reporting systems should have the nec­
essary safeguards to ensure the proper and 
nonduplicative reporting of laboratory results 
and diagnostic determinations. 
Sexual Assault and Abuse 
•	 All clinic staff should be familiar with provi­
sions of the state child abuse and neglect stat­
ute and their obligations under it. 
•	 Clinic staff members should be familiar with 
applicable STD and HIV confidentiality stat­
utes and should be sensitive to any limitations 
on the reporting of supplementary informa­
tion about suspected abuse cases. 
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Recommendations, continued 
•	 The clinic manual should specify the manage­
ment of patients of alleged abuse, listing the 
required examination and proper handling of 
laboratory specimens for evidence, and report­
ing procedures. 
•	 Testing of abused or assaulted patients should 
be performed using the most specific tests 
available. 
•	 Clinics should set up a mechanism for refer­
rals to perform additional confirmatory test­
ing necessary to make a definite diagnosis. 
•	 Clinics should have a patient advocate who 
maintains links with victim’s assistance pro­
grams. 
Domestic Violence 
•	 All clinic staff members should be familiar 
with domestic violence statutes. 
•	 STD programs should incorporate domestic 
violence issues into their staff training. 
SCREENING 
Because many sexually-transmitted diseases are asymp­
tomatic, seeking care when symptoms occur is unlikely 
to lead to detection of most infections. Therefore, 
screening is critical for early detection and treatment. 
Although persons with STDs may not specifically seek 
infection-related treatment services, they do visit sev­
eral health care settings for other purposes. These vis­
its are an opportunity to diagnose and treat STDs. 
Examples of healthcare settings in which this screen­
ing can take place are family planning clinics, prena­
tal clinics, emergency rooms and walk-in clinics, com­
munity and migrant-worker health centers, clinics for 
adolescents, school-based clinics, clinics in correctional 
facilities, and primary-care provider offices. 
Screening criteria have been defined in national 
guidelines. But, in the absence of well-defined screen­
ing criteria, prevalence of infections should be assessed 
in clinical settings that serve people who are poten­
tially at risk. In populations where the prevalence is 
high (i.e., >2%), routine screening should be imple­
mented. Previously described examples of populations 
at risk are people who abuse illicit drugs, who have 
more than one sex partner per year, who are entering 
correctional facilities, and who live in communities 
with high rates of STDs. Determination of risk should 
also take into account the prevalence of HIV infection 
in the population being considered. 
Early detection and treatment of STDs among HIV-
infected persons can be effective and cost-beneficial in 
reducing HIV transmission for three reasons: most 
STDs promote increased shedding of HIV (Cohen, 
1997); the number of HIV-infected persons is smaller 
than the number of persons at risk for becoming in­
fected; and HIV-infected persons often receive regular 
medical care. All HIV-infected persons who are hav­
ing unprotected sex should be screened for other sexu­
ally-transmitted infections, including gonorrhea, 
chlamydial infection, syphilis, and trichomoniasis. 
Persons with HIV/AIDS should be assessed for genital 
herpes, informed about the symptoms of herpes, and 
counseled particularly to avoid sex during periods with 
symptoms of reactivation of genital herpes, which are 
associated with higher rates of HIV viral shedding 
(Schacker, 1998). Sexually active, HIV-infected persons 
should be screened annually. If the person’s risk be­
havior, risk behavior of the person’s partner(s), and 
the incidence of STDs in the local population place 
the HIV-infected person at greater risk for another 
sexually-transmitted infection, screening should occur 
more frequently. 
Guidelines for screening for the major sexually-
transmitted pathogens and for screening specific popu­
lation groups (e.g., adolescents) have been recently 
published (U.S. Preventive Task Force, 1996; Ameri­
can Medical Association, 1992). The Advisory Com­
mittee for HIV and STD Prevention endorses these 
existing screening guidelines and extends them to in­
clude the following recommendations: 
•	 All sexually active females less than 25 years old 
who visit a health care provider for any reason 
should be screened for chlamydia and gonorrhea at 
least once per year, unless screening in that setting 
has been documented to yield a low prevalence of 
infection (i.e., <2% using sensitive tests). 
•	 All young, sexually active men should be screened 
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routinely for chlamydial and gonococcal infections 
in an acceptable fashion which may include using 
urine as a specimen for screening. 
•	 Older males and females at risk because of their 
behavior should be screened for chlamydial infec­
tion and gonorrhea at least once per year when vis­
iting health care providers for any reason. 
•	 Serologic screening for syphilis should be conducted 
in all persons at risk (e.g., persons who exchange 
sex for money or drugs, persons with multiple sex 
partners or partners who have exchanged sex for 
money or drugs, persons admitted to jails, and us­
ers of illicit drugs). 
•	 Sexually active, HIV-infected persons should be 
screened at least annually for STDs. 
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Appendix ML–A 
CLIA 
CLIA Background 
CLIA has categorized more than 150,000 test systems 
based on the complexity of their method. The three 
test categories are: 1) waived complexity; 2) moderate 
complexity, with a subcategory of provider performed 
microscopy; and 3) high complexity. Criteria for clas­
sification into these levels include (1) degree of knowl­
edge needed to perform the test; (2) training and ex­
perience required; (3) complexity of reagent and 
materials preparation; (4) characteristics of operational 
steps; (5) characteristics and availability of calibration, 
quality control, and proficiency testing materials; (6) 
troubleshooting and maintenance required; and (7) 
degree of interpretation and judgement required in the 
testing process. 
The subcategory of Moderate Complexity, Provider 
Performed Microscopy (PPM), was created in 1993 
and includes the following microscopic tests: 
•	  all direct wet mount preparations for the presence 
or absence of bacteria, fungi, parasites, and human 
cellular elements; 
•	 all potassium hydroxide (KOH) preparations; 
•	 pinworm examinations, fern tests, post-coital di­
rect, qualitative examinations of vaginal or cervi­
cal mucous; 
•	 urine sediment examinations; 
•	 nasal smears for granulocytes; 
•	 fecal leukocyte examinations; and 
•	 qualitative semen analysis (limited to the presence 
or absence of sperm and detection of motility). 
These are procedures limited to bright field or phase-
contrast microscopy with unique characteristics that 
are not adequately addressed within the moderate com­
plexity category. For example, specimens are labile and 
need to be examined immediately so the accuracy of 
the test results is not compromised. In addition, there 
are no recognized quality control procedures available 
for these tests. Initially, providers included only doctors 
of medicine, osteopathy, or podiatric medicine. The cat­
egory was modified later to include dentists, nurse prac­
titioners, nurse midwives, and physician assistants. 
Some test systems have been waived or exempted 
from CLIA requirements. These tests are waived be­
cause they (1) have been approved by the Food and 
Drug Administration (FDA) for home use, (2) use 
methods that are so simple and accurate that the like­
lihood of erroneous results by the user is negligible, or 
(3) DHHS has determined they pose no unreasonable 
risk of harm to the patient, if performed incorrectly. 
Waived tests that may be used in STD include dip­
stick/tablet urinalysis, and urine pregnancy tests. In 
September, 1995, the Centers for Disease Control and 
Prevention proposed criteria to be used to determine 
whether test systems could be waived from CLIA re­
quirements. Currently, requests for waiver are reviewed 
using these proposed waiver criteria. 
Certification 
Implementation and enforcement of the Clinical Labo­
ratory Improvement Amendments (CLIA) are the re­
sponsibility of the Health Care Financing Administra­
tion (HCFA). Laboratories must first register, after 
which HCFA surveys the laboratory, issues a certifi­
cate of compliance, and collects the appropriate fees. 
As waived and PPM laboratories are not subject to 
routine inspections, they apply to HCFA directly for 
the certificate. Laboratories may be issued a certifi­
cate of accreditation by a HCFA-approved organiza­
tion or HCFA-approved state program in lieu of HCFA 
certification. Under CLIA, HCFA is also responsible 
for establishing proficiency testing programs, approv­
ing accreditation programs, and exempting state ap­
plications when indicated. 
Exemption to Certification 
It is generally accepted that CLIA regulations affect 
the staffing needed for STD clinic laboratories and who 
is allowed to perform certain tests, such as the Rapid 
Plasma Reagin Card Test for syphilis (RPR). In addi­
tion, fees collected by HCFA for certification have to 
be factored into the budgets of STD clinic laborato-
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CLIA, continued 
ries, as well as costs for enrollment in proficiency test­
ing programs. Laboratories that obtain a certificate 
for moderate or high complexity testing must enroll 
in a proficiency testing program and pass proficiency 
testing for each certified speciality and subspeciality, 
e.g., syphilis serology. Each laboratory must establish 
and follow written quality control and quality assur­
ance procedures to ensure accurate and reliable results 
and to monitor their testing process. 
An exemption to this certification requirement is 
available for limited public health testing (LPHT). This 
exemption allows not-for-profit or federal, state, or 
local government laboratories at multiple sites to file 
a single application. This certificate provides adminis­
trative and financial relief because: (l) only one regis­
tration fee is required (rather than separate fees for 
each site); (2) the inspection fee is determined on the 
total test volume and specialities among all sites; (3) 
only one site must enroll in proficiency testing (al­
though other sites must compare performance). 
Thus, the LPHT reduces the costs of registration 
fees, training, proficiency testing, and personnel re­
quirements. A number of states currently have pro­
grams in effect to help maintain STD laboratory test­
ing by enrolling local public health laboratories in 
multiple site certificates operated by the state public 
health laboratory. In these states, the state laboratory 
director often serves as the laboratory director for all 
of the smaller public health laboratories. Necessary 
training is conducted in the state laboratory or at a 
regional location. All programs report that they per­
form at least one on-site visit per year for each LPHT 
laboratory. Because there has been up to 150 sites per 
certificate, concern has been raised about effective su­
pervision of these laboratories. 
CLIA ‘88 Test Categorization 
As stated earlier, Test Categorization criteria are de­
fined as (1) degree of knowledge needed to perform 
the test; (2) training and experience required; (3) com­
plexity of reagent and materials preparation; (4) char­
acteristics of operational steps; (5) characteristics and 
availability of calibration, quality control, and profi­
ciency testing materials; (6) troubleshooting and main­
tenance required; and (7) degree of interpretation and 
judgement required in the testing process. 
Test categorization is a continuing process. New 
products are categorized, and names of test system 
manufacturers change. The Test Categorization Data­
base is updated monthly. 
A current list of all categorized test systems is found 
on the Internet at: 
www.phppo.cdc/dls/clia/ 
If you have questions regarding test systems on the 
test list or how to gain access to the list, please call 
(770) 488-8155. 
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CLIA ‘88 Personnel Requirements 
The Clinical Laboratory Improvement Amendments (CLIA ‘88) have established standards for personnel, qual­
ity control, quality assurance, patient test management, and proficiency testing based on the complexity of the 
testing performed. The following table summarizes the personnel requirement for Moderate Complexity, in­
cluding Provider Performed Microscopy (PPM), and High Complexity laboratories. Laboratories performing 
only waived testing do not have any personnel requirements. 
Test Complexity Level and Personnel* Education, Experience, and Training Requirements 
Waived None 
Provider Performed Microscopy (PPM) 
Laboratory Director  • M.D., D.O., D.P.M., D.D.S., Nurse Midwife, Nurse Practitioner, 
Physician Assistant. 
Testing Personnel  • M.D., D.O., D.P.M., D.D.S., Nurse Midwife, Nurse Practitioner, 
Physician Assistant. 
Moderate Complexity 
Laboratory Director 
Technical Consultant 
Clinical Consultant 
Testing Personnel 
• M.D. or D.O. certified in anatomic or clinical pathology or both or 
• M.D., D.O., D.P.M. and training consisting of 1 year directing or 
supervising non-waived lab testing or at least 20 CMEs in laboratory 
practice or lab training in medical residency equivalent to 20 CMEs or 
• Ph.D. and certification by board approved by HHS or 1 year 
directing or supervising non-waived lab testing or 
• Master’s in Science plus 1 year laboratory training or experience 
or both and 1 year supervisory experience in non-waived testing or 
• Bachelor’s in a Science plus 2 years laboratory training or experience 
or both and 2 years supervisory experience in non-waived testing or 
• Grandfather provisions. 
• M.D. or D.O. certified in anatomic or clinical pathology or both or 
• M.D., D.O., D.P.M. and 1 year laboratory training or experience or 
both in non-waived testing or both in the designated specialty or 
subspeciality or 
• Ph.D. and 1 year of laboratory training or experience or both, in 
non-waived testing in the designated specialty or subspeciality or 
• Bachelor’s in Science and 2 years laboratory training or experience 
or both in non-waived testing in the designated specialty or 
subspeciality. 
•  Qualify as a Laboratory Director as stated above or 
•  M.D., D.O., D.P.M. 
•  M.D., D.O., Ph.D., Master’s or Bachelor’s in Science or 
•  Associate degree in Science or 
•  High school graduate or GED and military trained or 
•  High school graduate or GED and documentation of training 
appropriate for testing performed 
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Test Complexity Level and Personnel* Education, Experience, and Training Requirements 
High Complexity 
Laboratory Director 
Technical Supervisor 
Clinical Consultant 
General Supervisor 
Testing Personnel 
• M.D. or D.O. certified in anatomic or clinical pathology or both or 
• M.D., D.O., D.P.M. and 1 year of laboratory training during medical 
residency or 2 years experience directing or supervising high 
complexity testing or 
• Ph.D. and certification by board approved by HHS 
• Grandfather provisions. 
• M.D. or D.O. certified in anatomic or clinical pathology or both or 
• M.D., D.O., D.P.M. and at least 1 year of laboratory training or 
experience or both in high complexity testing of the specialty or 
subspeciality and for microbiology, a minimum 6 months experience in 
high complexity testing within the specialty is required or 
• Ph.D. and at least 1 year of laboratory training or experience or both 
in high complexity testing of the specialty or subspeciality and for 
microbiology, a minimum 6 months experience in high complexity 
testing within the subspeciality is required or 
• Master’s in Science and at least 2 years of laboratory training or 
experience or both in high complexity testing of the specialty or 
subspeciality and for microbiology, a minimum 6 months experience in 
high complexity testing within the subspeciality is required or 
• Bachelor’s in Science and at least 4 years of laboratory training or 
experience or both in high complexity testing of the specialty or 
subspeciality and for microbiology, a minimum 6 months experience in 
high complexity testing within the subspeciality is required. 
• Qualify as a Laboratory Director as stated above or 
• M.D., D.O., D.P.M. 
• Qualify as Laboratory Director or Technical Supervisor as stated above or 
• M.D., D.O., D.P.M., Ph.D., M.S., B.S., and at least 1 year of laboratory 
training or experience, or both, in high complexity testing or associate 
degree in laboratory science, or equivalent or 
• Grandfather provisions. 
• M.D., D.O., D.P.M., Ph.D., M.S., B.S. or 
• A.S. or appropriate education and training (specified in 
493.1489(b)(2)(ii)) or 
• High School graduate with accredited laboratory training or military 
training or 
•  Grandfather provisions. 
*Personnel also must possess a current 
license issued by the state if such licensing exists. 
Moderate Complexity level testing covers most of the stat STD tests requested routinely. Under professional training requirements 
for a laboratory holding a certificate for moderate complexity testing only, the director of the laboratory would need to meet the 
requirements listed above. The director also may serve as the technical consultant or as the clinical consultant and may perform 
testing. Other testing personnel would need to meet the training requirements listed above for moderate complexity testing. 
Appropriate training might be acquired on-the-job, through attendance at formal courses at one of the STD Prevention Training 
Centers, or through the National Laboratory Training Network, institutions of higher learning, state or regional laboratories (formal 
or informal), satellite video training sessions (distance learning), or use of computerized self-study training products. 
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Commonly Used Stat Tests—Useful Tips 
SALINE AND 10% KOH WET MOUNTS , VAGINAL PH 
Test Principles 
Vaginal secretions or exudates may be directly exam­
ined for the presence of yeast, Trichomonas vaginalis, 
or clue cells by using saline wet mounts (Stamm, 1988). 
KOH mounts are used to dissolve surrounding mucus 
or tissue for easier examination of specimens for yeast 
or fungal elements. In addition, a characteristic amine 
odor may be observed in patients with bacterial 
vaginosis and T. vaginalis when vaginal secretions are 
combined with 10% KOH. Vaginal pH greater than 
4.5 also indicates presence of bacterial vaginosis or 
trichomoniasis. 
Specimen Collection 
Vaginal secretions and other appropriate specimens 
should be collected on a swab, which may be used for 
immediate examination. If the swab is placed in ap­
proximately 1 mL of sterile saline in a small test tube, 
this saline solution may be used for the wet prep and 
KOH prep. For determination of vaginal pH, touch 
pH paper to vaginal wall or to discharge in speculum. 
Avoid contact with cervical mucus because it has a 
high pH. Match pH paper to color scale to determine 
the pH value. 
Procedure 
1. Emulsify the specimen by immersing the end of the 
swab into the tube containing saline to make a heavy 
suspension. 
2. Place specimen on a slide and cover with a cover­
slip carefully to avoid trapping air bubbles under 
the coverslip. 
3. Examine the slide immediately for the presence of 
yeast, trichomonads, or clue cells. Scan first on low 
power with reduced light; Trichomonads can often 
be identified on low power. Switch to high power 
to check for the presence of yeast cells, pseudo hy­
phae, clue cells, or less vigorously motile tri­
chomonads. A KOH prep may be needed to better 
examine for yeast in purulent specimens. 
4. The KOH prep is made by placing the specimen on 
a slide, adding 10% KOH, and mixing with a 
wooden applicator or swab. Cover with a coverslip 
and avoid trapping air bubbles. Sniff for a “fishy” 
odor. 
5. Use low power to scan for yeast and confirm on 
high power. 
Examination of Slide and Interpretation of 
Results 
1. Trichomonads are only seen in the saline prep; they 
are lysed (broken down) by KOH. They have ame­
boid properties, are generally ovoid, slightly larger 
than polymorphous nuclear leukocytes (PMNs), and 
in fresh preparations are recognized by their jerky, 
swaying movement. The presence of even one or­
ganism is diagnostic. Actively motile trichomonads 
are easily seen on low power. High power is neces­
sary to detect less vigorously moving organisms 
when only the flagella or undulating membrane may 
be in motion. Numerous PMNs are often present. 
2. Numerous “clue” cells and few or no PMNs are 
indicative of bacterial vaginosis. “Clue cells” are 
irregularly bordered squamous epithelial cells whose 
cell outlines are obliterated by sheets of small bac­
teria. “Clue” cells are seen in saline, not KOH preps. 
3. Yeast may be obscured by epithelial cells in the sa­
line wet mount, but pseudo hyphae and budding 
yeast cells are sometimes visible. PMNs may or may 
not be visible. In the KOH preparation, budding 
yeasts and pseudo hyphae are more easily seen be­
cause epithelial cells and PMNs have been lysed. 
Use low power to scan for yeasts and confirm on 
high power. Care should be taken in interpreting 
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apparent results; artifacts are common in KOH 
preps as a result of cell degeneration, air bubbles, 
crystallization, and glycerol.
 Sources of Error 
The following errors in technique will decrease the 
sensitivity of the wet mount for detection of T. 
vaginalis: 
1. Collection of the specimen from the endocervix 
2. The use of cool saline (saline should be at room 
temperature). 
3. Delay in reading the smear 
4. Contamination of the saline prep with KOH 
5. Too much saline on the slide, causing the material 
to move rapidly across the field 
6. Making a preparation too thick 
7. Failure to read the slide with condenser lowered 
(too much light) 
8. Examination of only a small area of the slide. 
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GRAM STAIN FOR MICROORGANISMS 
Test Principles 
The Gram stain is the most commonly used stain in 
bacteriology. It is classified as a differential stain and 
serves to distinguish the gram-positive from the gram-
negative bacteria. The original Gram stain technique 
has been modified a number of times, and the usual 
recommended procedure is the Hucker modification. 
Although the Gram stain is among the least com­
plicated and least time-consuming of all microbiologi­
cal tests, the information that may be obtained from a 
properly stained smear of a specimen from a client is 
one of the most valuable aids to the clinician and the 
laboratorian. A properly performed stain can provide 
important diagnostic information concerning the type 
of organisms present, and the therapy to initiate while 
waiting for other test results. In the stat STD labora­
tory setting, the Gram stain is used to aid in the diag­
nosis of gonorrhea, candidal vulvovaginitis, and bac­
terial vaginosis, and in the assessment of urethritis, 
cervicitis, proctitis, and other infections characterized 
by infected discharges. Both the numbers of polymor­
phonuclear leukocytes (PMNs) and microbial flora 
present can be assessed (Stamm, 1988). 
Specimen Collection 
Male urethral smear 
Patient should not urinate prior to specimen collec­
tion. Insert a small swab into the urethra. 
Cervical smear 
Wipe the cervix before collecting the specimen to re­
duce the amount of vaginal bacteria and cells in the 
smear. 
Rectal smear 
Use an anoscope to collect the specimen and sample 
areas containing pus. 
Smear Preparation 
To prepare a direct smear from a patient, roll swab 
with patient's specimen on a clean glass slide, making 
a thin spread; do not smear (leukocytes may be dis­
rupted) or prepare a thin smear from a culture in a 
drop of water on the slide. Air dry the smear and fix 
to the glass by rapidly passing the slide through a Bun­
sen burner flame two or three times. The slide should 
be slightly warm to the skin on the back of the hand. 
Do not use swab from a DNA probe or Pap smear for 
a Gram stain. 
Staining Schedule 
1. Stain smears with crystal violet ammonium oxalate. 
2. Wash in tap water. 
3. Apply Gram's iodine solution. 
4. Wash in tap water. 
5. Decolorize with 95% ethyl alcohol until washes are 
no longer blue 
6. Wash and shake off excess water. 
7. Apply counterstain of safranin. 
8. Wash in tap water and blot dry. 
Examination of Slide and Interpretation of 
Results 
1. Scan the stained smear with the 10X objective to 
locate the best area for viewing. 
2. Examine the smear microscopically with the oil 
immersion objective. 
3. Gram-positive organisms appear purple and gram-
negative organisms appear red. Search for organ­
isms and count PMNs. Cells and mucus should stain 
pink. Yeast stain purple. Bacteria are characterized 
as gram-positive (purple) or gram-negative (pink) 
and as cocci (round), bacilli (rod shaped), or cocco­
bacilli (in between rods and cocci). 
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4. Control slides of representative gram-positive and 
gram-negative organisms should be examined each 
time Gram stains are performed. 
Note: If using commercial kits or reagents, follow 
manufacturer's instructions in the product insert. 
Sources of Error 
1. Scrubbing, not rolling, the swab across the slide may 
destroy cellular morphology. 
2. Failure to heat-fix the slide may cause material to 
wash off during staining. 
3. Overheating the slide may cause artifacts to be 
stained and cells to be distorted. 
4. Use of Gram’s Iodine solution beyond expiration 
date (shelf life of reagent at room temperature is 
approximately 90 days). 
5. Over-decolorizing the slide may cause gram-posi­
tive organisms to appear gram-negative. 
6. Under-decolorizing the slide may cause gram-nega­
tive organisms to appear gram-positive. 
7. Reagents contaminated with microorganisms may 
give erroneous results. 
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EXAMINATION OF SPECIMENS BY DARKFIELD MICROSCOPY 
Test Principles 
A diagnosis of syphilis is confirmed by using darkfield 
microscopy to demonstrate Treponema pallidum in 
material from suspected lesions or regional lymph 
nodes (Creighton, 1990). A positive darkfield result is 
an almost certain diagnosis of primary, secondary, or 
early congenital syphilis. In primary syphilis, the 
darkfield examination may provide a means by which 
to identify the etiologic agent of syphilis and diagnose 
the disease before antibodies to T. pallidum can be 
detected. 
Proper equipment and adequately trained person­
nel are required to demonstrate the presence of T. 
pallidum in lesion material by darkfield microscopy. 
The examination of several slides may be required. 
Principles of Darkfield Microscopy 
The standard brightfield microscope can be 
equipped for darkfield examination by replacing the 
brightfield condenser with a darkfield condenser. Illu­
mination for darkfield microscopy is obtained when 
light rays strike the object in the field at such an ob­
lique angle that no direct rays enter the microscope 
objective, only the rays reflected from the object. There­
fore, the object appears self-luminous against a dark 
background, hence the term darkfield. When a fluid 
containing particles, including bacteria or treponemes, 
is placed on a slide, the oblique rays are reflected from 
the surfaces upward into the barrel of the microscope; 
these particles appear brightly illuminated against a 
black background. 
Specimen Collection 
Lesions in general 
a. Remove any scab or crust covering the lesion. 
b. Secondary infection exudate, if any, should be re­
moved with a gauze sponge. 
c. If necessary, compress the base of the lesion or ap­
ply a suction cup to the lesion to promote the accu­
mulation of tissue fluid on the ulcer surface. 
d. Apply a glass slide to the oozing lesion, or use a 
sterile bacteriological loop to transfer the fluid from 
the lesion to the glass slide. Three specimens should 
be collected from each lesion. 
e. Place a cover glass on the specimen and flatten or 
depress it evenly on the slide, using the blunt end of 
an applicator stick to remove air bubbles. 
f. Examine the slide immediately. 
g. To prevent drying, place additional slides with speci­
mens in a moist chamber, such as a large plastic 
petri dish containing a moistened paper towel. 
The slide preparations should not contain a large vol­
ume of fluid (large volumes cause a rapid liquid flow 
across the field), nor should the preparation be so thin 
that it begins to dry before and adequate examination 
can be made. 
Microscope adjustment should always be completed 
and the microscope should be in satisfactory working 
condition BEFORE collecting the patient's specimen 
for examination. 
Procedure for adjustment of the microscope 
1. Place a blank slide on the stage and raise the sub­
stage containing the darkfield condenser to its maxi­
mum height. The top of the darkfield condenser 
should be slightly below the level of the stage but 
as close to the glass slide as possible without push­
ing it up. Remove blank slide. 
2. Turn on the variable transformer to produce maxi­
mum light intensity. 
3. Lower the substage slightly and place immersion 
oil on the top of the condenser. 
4. Place the slide with specimen (gingival scraping) on 
the stage and use the mechanical slide carrier to 
center the specimen over the condenser. 
5.	 Slowly raise the substage until there is a complete 
oil contact between the top of the condenser and 
the bottom of the slide. 
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6.	 Rotate the nosepiece to center the low power ob­
jective over the specimen. 
7.	 Bring the specimen into focus by using the coarse 
adjustment knob. 
8.	 At this point, center the light in the field by rotat­
ing the two centering screws located at the base of 
the darkfield condenser. 
9.	 Focus the darkfield condenser by slightly raising 
or lowering the substage until you observe the 
smallest diameter of the circular area of intense 
light. 
10. Rotate the nosepiece until the high-dry objective 
is in place over the specimen. 
11. Bring the specimen into focus by using the fine 
adjustment knob only. 
12. If a satisfactory image is obtained, place a SMALL 
drop of immersion oil on the cover glass. 
13. Rotate the nosepiece until the oil-immersion ob­
jective is in place over the specimen and is in con­
tact with the oil on the cover glass. If the oil-im­
mersion objective is equipped with an iris 
diaphragm, close the diaphragm to reduce the nu­
merical aperture below that of the darkfield con­
denser. A funnel stop will serve the same purpose 
in an oil-immersion objective without an iris dia­
phragm. 
14. Bring the specimen into focus by using the fine 
adjustment knob only. The light intensity from the 
illuminator may be decreased or increased slightly 
to give the best contrast. 
Examination of the client’s specimen for 
T. pallidum 
1. Place the slide to be examined (client’s specimen) 
on an adjusted darkfield microscope. Since minor 
adjustments may be required, it may be necessary 
to repeat steps already described. 
2. Search the entire specimen methodically with the 
high-dry objective for spiral organisms that have 
the characteristic morphology and motility of T. 
pallidum. (T. pallidum is a thin, delicate, spiral or­
ganism, with 6- 20 (average 10) rigid, tightly wound 
coils, capable of extreme bending which occurs in 
the middle and is stiffly executed, snapping back to 
its original form, like the bending of a coil spring. 
The average organism is slightly longer than the 
diameter of a red blood cell. Coil appearance is 
maintained despite active motility of the organism. 
It may spin rapidly about the longitudinal axis (like 
a corkscrew) without any forward or backward move­
ment, move slowly forward and backward without 
obvious change in direction of rotation or pitch of 
coils, or the organism may move slowly, threading its 
way corkscrew-fashion in viscous material. A spring-
like rigidity is constant, and T. pallidum does not 
move rapidly from place to place with a serpentine 
motion. Any coarsely wound spiral organism ex­
hibiting great flexion and rapid movement from 
place to place is NOT T. pallidum. Search carefully, 
systematically, and exhaustively before making a nega­
tive report. A typical systematic scheme for search­
ing the specimen adequately is to start in the upper 
left corner of the cover glass area, traverse to the 
right edge of the cover glass, drop down slightly and 
traverse to the left; continue to search in this pattern, 
until the entire cover glass area has been searched. 
3. At least 10 minutes should be spent on each of the 
three specimens collected before a negative report 
is rendered. The additional slides may be placed in 
a moist chamber (moistened paper towels placed in 
a Petri plate, for example) until examined. 
4. Safety precautions should be followed, including 
gloves for the microscopist and proper biohazard 
discard containers for the disposal of slides. 
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Reporting and Interpretation of Results 
Report Results 
Darkfield positive Organisms that have the 
characteristic morphology and 
motility of T. pallidum 
Darkfield negative 
(inconclusive) 
No treponemal organisms or 
spiral organisms; no organisms 
with characteristic morphology 
and motility of T. pallidum 
Darkfield 
unsatisfactory 
No T. pallidum found, but 
specimen has too many refractile 
elements (blood cells, air 
bubbles, tissue fragments), or 
specimen is drying. 
Every genital lesion should be considered syphilitic 
until proven otherwise. Extragenital lesions charac­
terized by indolence (causing little or no pain), indu­
ration (firm or hard), and regional lymphadenopathy 
should be regarded as probably syphilitic. Failure 
to find the organism does not exclude a diagnosis of 
syphilis. 
Negative results may mean that 
1. The number of organisms was insufficient for de­
tection. 
2. The patient has received antitreponemal drugs lo­
cally or systemically. 
3. The lesion is “fading” or approaching natural reso­
lution or disappearance. 
4. The lesion is one of late syphilis. 
5. The lesion is not syphilitic. 
Sources of Error 
Preparation Errors 
a. If the specimen contains too many blood cells, air 
bubbles, or tissue fragments, these refractile ele­
ments can obscure the presence of T. pallidum. 
b. If the microscope slides are not of the proper thick­
ness, or if slides and cover glasses are dirty or 
scratched, it will be difficult to obtain a good 
darkfield. 
c. If there is excessive fluid in the specimen or too little 
fluid, the examination will be difficult. 
Microscopy Errors 
a. If immersion oil is not placed between the condenser 
and slide, no light will reach the specimen. 
b. If the darkfield condenser is not properly centered 
or focused the illumination will not be optimum. 
c. If immersion oil is on the lens of the low-power or 
high-power objectives, the resulting view will be 
hazy. 
Interpretation Errors 
a. If one is unfamiliar with the morphology and mo­
tility characteristics of T. pallidum, a false-positive 
or false- negative report could be issued. 
b. If one mistakes nonspecific spiral organisms or ob­
jects, tissue debris, fibrin strands, and other extra­
neous objects for treponemes, a false-positive re­
port could be issued. 
c.	 If one sees occasional erratic movement of T. 
pallidum or no movement at all, too much time may 
have elapsed between making the slide and exam­
ining it. 
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RPR CARD TEST 
Test Principles 
The rapid plasma reagin (RPR) 18-mm circle card test 
is a macroscopic, nontreponemal flocculation card test 
used to screen for syphilis (Creighton, 1990). The an­
tigen is prepared from a modified Venereal Disease 
Research Laboratory (VDRL) antigen suspension con­
taining choline chloride to eliminate the need for heat 
inactivation of serum, ethylenediaminetetraacetic acid 
(EDTA) to enhance the stability of the suspension, and 
finely divided charcoal particles as a visualizing agent. 
For the test, the RPR antigen is mixed with unheated 
or heated serum or with unheated plasma on a plas­
tic-coated card. The RPR test measures antibodies to 
lipoidal material released from damaged host cells as 
well as to lipoprotein-like material, and possibly car­
diolipin released from the treponemes. If antibodies 
are present, they combine with the lipid particles of 
the antigen, causing them to agglutinate or clump. The 
charcoal particles coagglutinate with the antibodies 
and show up as black clumps against the white card. 
If antibodies are not present, the test mixture is uni­
formly gray. Without some other evidence for the di­
agnosis of syphilis, a reactive nontreponemal test does 
not confirm T. pallidum infection. 
Specimen Collection 
Serum—Collect whole blood into a clean, dry tube 
without an anticoagulant. 
Plasma—Collect blood in a tube containing EDTA as 
an anticoagulant. Completely fill the tube or collect 
blood until the vacuum in the collection tube has been 
exhausted. 
Label each specimen with patient identifier, and date. 
Procedure 
Qualitative Test 
1. To prepare antigen for testing, attach the hub of 
the dispensing needle to the fitting on the plastic 
dispensing bottle. Shake the antigen ampule to re­
suspend the particles. Open the ampule. Squeeze 
the dispensing bottle to collapse it. Insert the needle 
into the ampule and withdraw all the antigen sus­
pension into the dispensing bottle. 
2. Place serum or plasma onto a 18-mm circle of the 
RPR test card, using a disposable Dispenstir or a 
safety pipetting device. 
3. Using the inverted Dispenstir (closed end) or flat 
toothpicks, spread the serum or plasma to fill the 
entire circle. Do not spread the specimen beyond 
the confines of the circle. 
4. Gently shake the antigen dispensing bottle to re­
suspend the particles. 
5. Holding the dispensing bottle and needle in a verti­
cal position, dispense several drops to clear the 
needle of air. Then add antigen suspension to each 
circle containing serum or plasma. Do not mix. 
6. Place the card on the mechanical rotator under a 
humidifying cover. Rotate the card. 
7. Immediately remove the card from the rotator; 
briefly rotate and tilt the card by hand to aid in 
differentiating nonreactive from minimally reactive 
results. 
8. Perform the quantitative test on serum specimens 
showing any degree of reactivity (clumping) or 
“roughness.” 
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Reading and Reporting of Qualitative Results 
1. Read the test reactions in the “wet” state under a 
high-intensity incandescent lamp. Read the test 
without magnification. 
2. Report the results as follows: 
Reading Report 
Characteristic clumping ranging Reactive (R) 
from marked and intense (reactive) 
to slight but definite (minimally to 
moderately) reactive 
Slight roughness or no clumping Nonreactive (N) 
Note: Only two reports with the RPR card test are 
possible: Reactive, no matter how much clumping, 
or Nonreactive. 
Interpretation of Results 
1. The RPR card test is an aid in the diagnosis of syphi­
lis. Clinicians combine the RPR card test with re­
sults of other serologic tests, darkfield examinations, 
clinical signs and symptoms, and risk factors in ar­
riving at a syphilis diagnosis. Without some other 
support for the diagnosis of syphilis, a reactive RPR 
card test is commonly unrelated to Treponema 
pallidum infection. The predictive value of a reac­
tive RPR card test in a serologic diagnosis of syphi­
lis is increased when combined with a reactive tre­
ponemal test, such as the fluorescent treponemal 
antibody absorption (FTA-ABS) test. 
2. A reactive RPR card test may suggest past or present 
infection with a pathogenic treponeme; however, it 
may also be a false-positive reaction. False-positive 
reactions can result from laboratory error as well 
as serum antibodies unrelated to syphilis infection. 
Technical errors are detected by a nonreactive RPR 
card test with a second serum specimen. False-posi­
tive RPR card tests from infections with 
nontreponemal diseases or other disease conditions 
are identified by an accompanying nonreactive tre­
ponemal test. 
3. A nonreactive RPR card test without clinical evi­
dence of syphilis may suggest no current infection 
or an effectively treated infection. A nonreactive 
RPR card test with clinical evidence of syphilis can 
be seen in early primary syphilis; in secondary syphi­
lis, as a result of the prozone reaction (see test limi­
tations); and in some cases of late syphilis. A 
nonreactive RPR card test result does not rule out 
an incubating syphilis infection. 
4. When the quantitative RPR card test is performed 
on patients with syphilis, a fourfold rise in titer on 
a repeat specimen may suggest an infection, a rein­
fection, or a treatment failure; a fourfold decrease 
in titer in early syphilis usually indicates adequate 
syphilis therapy. 
5. All reactive qualitative RPR card tests should be 
diluted to an endpoint and the endpoint titer re­
ported. 
Sources of Error 
1. If the temperatures of the sera, reagents, or testing 
area are less than 23%C (73%F), test reactivity 
decreases; if temperatures are greater than 29%C 
(85%F), test reactivity increases. 
2. If the speed of the mechanical rotator is too fast or 
too slow, improper antigen-antibody interaction will 
cause unpredictable test results. 
3. If the time of 	 rotation is too long test reactivity 
may be increased, or if too short test reactivity may 
be decreased. 
4. If the card is excessively rotated and tilted (to-and­
fro motions) by hand after removal from the rota­
tor, a false- reactive result may occur. 
5. If lighting produces a glare on the card, the reac­
tions may be obscured. 
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6. If the antigen is outdated or not adequately tested 
for standard reactivity, the results may be unpre­
dictable. 
7. If the serum is unevenly spread in the circle, the 
antigen and antibody may not mix properly. 
8. If hemolyzed, contaminated, or improperly collected 
serum or plasma samples are tested, the reaction 
may be masked. 
9. If the moistened humidifying cover is not used to 
cover tests as they are being rotated, proper humid­
ity will not be maintained, and test components may 
dry on card, and false reactive results may occur. 
Test Limitations 
1. The RPR card test cannot be used to test spinal flu­
ids. 
2. A prozone reaction may be encountered occasion­
ally. In a prozone reaction, complete or partial inhi­
bition of reactivity occurs with undiluted serum 
(maximum reactivity is obtained only with diluted 
serum). The prozone phenomenon may be so pro­
nounced that only a rough reading is produced in 
the qualitative test by a serum that will be strongly 
reactive when diluted. All test specimens produc­
ing any degree of roughness or reactivity with the 
RPR card test antigen in the qualitative test should 
be retested by using the quantitative procedure. 
3. The RPR card test may be reactive in persons from 
countries where yaws, pinta or nonvenereal syphi­
lis is endemic. Generally, residual titers from these 
infections will be no higher than 1:4. 
4. Biological false-positive (BFP) reactions occur oc­
casionally with cardiolipin antigens, mainly in speci­
mens from persons who abuse drugs; who have dis­
eases such as lupus erythematosus, mononucleosis, 
malaria, leprosy, or viral pneumonia; or who have 
recently been vaccinated. 
5. Nontreponemal test titers of persons who have been 
treated in latent or late stages of syphilis or who 
have become reinfected do not decrease as rapidly 
as do those of the persons in the early stages of 
their first infection. In fact, these individuals may 
remain “serofast,” retaining a low-level reactive ti­
ter for life. 
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VENIPUNCTURE 
This appendix contains additional information on veni­
puncture that might be useful to a Program Manager 
in conducting venipuncture training. One element is a 
model training program which could be adapted to 
local areas. A second element is a list of equipment 
and supplies needed for training in venipuncture, which 
can also serve as a checklist for equipping a venipunc­
ture kit for field activity. The third element is a Perfor­
mance Evaluation Checklist with a step by step proce­
dure guide to evaluate the performance of a trainee in 
venipuncture. 
Suggested Components of a Venipuncture 
Training Program 
Lecture 
•	 Overview of Standard Precautions 
•	 Basic anatomy and physiology of the blood supply 
•	 Equipment and supplies 
•	 Venipuncture technique 
•	 Potential patient reactions to venipuncture and com­
plications 
•	 Interventions in caring for patient reactions and 
complications 
•	 Preparation for practicum 
•	 Evaluation 
Practicum 
•	 Venipuncture technique demonstration using train­
ing arm or student partner. 
•	 Venipuncture technique experiences in clinic and 
field setting with preceptor. 
Documentation 
•	 Skills checklist (venipuncture performance evalua­
tion) 
Venipuncture Equipment List for Field Activity 
Disease Intervention Specialists (DIS) should be able 
to draw blood in field settings as part of disease inves­
tigation or outreach activities. Appropriate equipment 
and supplies on hand to make up a fully-equipped veni­
puncture kit should include the following: 
•	 disposable examination gloves 
•	 eye protection 
•	 container of alcohol sponges or cotton balls 
•	 container of dry cotton balls 
•	 bandages or Band-Aids 
•	 vacutainer holder, vacutainer tubes, sterile needle, 
20-22 gauge 
•	 tourniquet (one-inch width preferred) 
•	 laboratory specimen slips; container for blood speci­
mens 
•	 puncture-resistant container for used needles 
•	 re-sealable plastic bag for other waste materials 
•	 spirits of ammonia (inhalant) 
•	 arm board (optional) 
•	 small rubber bands 
•	 small bottle of disinfectant or towelettes with dis­
infectant 
•	 venipuncture identification card, if needed or avail­
able (need varies from state to state) 
Technique for Procedure of Venipuncture 
The complete technique of venipuncture is contained 
in manuals or guides published by state departments 
of health in a number of states, e.g., Texas, Washing­
ton, and California. An outline of the technique of 
venipuncture procedure is contained in the following 
Venipuncture Evaluation Checklist. 
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Venipuncture Performance Evaluation 
Name ______________________________________________________________ Date ______________________ 
Instructions: 
1. Practice performing a venipuncture. 
2. Demonstrate the procedure for performing a venipuncture satisfactorily for the instructor. All steps must be 
completed as listed on the instructor’s Performance Check Sheet. 
S=Satisfactory; U=Unsatisfactory 
PROCEDURE S U COMMENT 
1. Wash hands with hand disin-fectant or soap and 
water, if available. 
2. Assemble equipment and materials. Place within 
easy reach. 
3. Identify patient properly. 
4. Explain venipuncture procedure to patient and 
position patient properly. 
5. Attach a sterile capped needle to vacutainer holder. 
Remove cap and position needle so that bevel faces 
upward. Inspect needle to see that point is smooth 
and sharp. 
6. Partially push vacutainer tube into needle in holder. 
7. Place the tourniquet around the patient’s arm above 
the elbow. CAUTION: Do not allow the tourniquet 
to remain in place for more than one minute. 
Instruct the patient to open and close the hand three 
times, making a fist when closing the hand the third 
time. 
8. Inspect the bend of the elbow to locate a suitable 
vein. Palpate the vein with the finger tip(s) to 
determine the direction of the vein, to estimate its 
size and depth, and any tendency to roll. 
9. Cleanse the skin of the puncture site using a alcohol 
prep or cotton ball soaked with alcohol. Allow alcohol 
to dry. 
10.Hold the needle at a 30 degree angle to the arm and 
insert the needle into the vein. Push the collecting 
tube onto the needle in the vacutainer holder to fill 
the tube with blood. Watch for blood flow into the 
vacutainer tube. 
11.Instruct the patient to open the fist as soon as the 
vein has been entered. 
12.Release the tourniquet when the desired amount of 
blood is obtained. 
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Venipuncture Performance Evaluation, continued 
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13.Place a dry cotton ball over the puncture site and 
withdraw the needle from the vein (do not press 
down on the needle). Instruct the patient to press 
the cotton ball over the wound for three to five 
minutes with arm extended upward. 
14.Adhere to Standard Precautions when disposing 
of all contaminated items including gloves, needles, 
vacutainer holder, cotton balls and other contaminat­
ed equipment. Note: Universal Precautions should be 
adhered to throughout procedure. 
15.Check patient to be sure that bleeding has stopped; 
apply band-aid if necessary. 
16.Clean work area with surface disinfectant. 
17.Wash hands with hand disinfectant or soap and 
water if available. 
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